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This dissertation describes new computational approaches at high resolution for practical 
structure-based drug discovery. It begins with a brief review of structure-based computational 
approaches for drug discovery in comparison with ligand-based ones, followed by a discussion 
of important applications in selecting drug-like compounds and predicting drug metabolites. 
Since three-dimensional target structures are crucial for structure-based drug discovery, a new 
methodology based on force fields for protein structure refinement was developed. This 
methodology employs the VSGB 2.0 energy model in combination with a robust protonation 
state assignment algorithm and efficient sampling strategies. High accuracy was obtained for 
predicting 2239 protein side chains and 115 14-20 residue loops. Given the precision and 
uniform robustness, this methodology is believed for the first time to be suitable to tackle 
practical problems in structure-based drug discovery. 
The VSGB 2.0 energy model was then applied in the development of a new accurate 
approach (IDSite) for predicting P450-mediated drug metabolism, a problem of great practical 
interest for drug discovery. IDSite is able to efficiently model induced-fit effects using flexible 
docking and constrained refinements. Sites of metabolism are determined based on the physical 
interactions between a P450 enzyme and the ligand. Preliminary tests with 56 compounds 
displayed both low false positive and low false negative rates, which demonstrate the high 




In conclusion, this dissertation presents new computational approaches at high resolution 
to problems related to structure-based drug discovery with unprecedented accuracy. Given such 
high accuracy, these approaches are very promising in addressing practical issues in 
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Chapter 1. Introduction 
Modern drug discovery is an extremely costly and lengthy process that involves many 
chemical and biological technologies. Among all these technologies, computational chemistry is 
becoming more and more widely used in identifying and optimizing molecules as potential drug 
candidates, helping to alleviate the considerable efforts required by the experiments. In the last 
decade, the advancement of high-performance computing (HPC) and the development of 
databases allowed medicinal chemists to access a much larger chemical space in silico than in 
vitro. This is leading to a gradual switch from traditional drug discovery approaches (such as 
semi-rational design, massive pharmacological screening, or even serendipity) towards more 
fruitful combinatorial approaches involving computer-aided techniques. Furthermore, while 
traditional non-virtual practices of drug discovery are facing problems such as high false positive 
rates,
4
 soaring cost, and slow procedures, computational techniques are becoming very attractive 
complements. Computational drug discovery has the following major advantages over traditional 
experimental approaches: 1) improving the hit rate and potency of candidates,
4
 2) reducing the 
demanding usage of assays, apparatus, and labor, and 3) streamlining the drug discovery process. 
It is believed that technology of computational chemistry has already permeated today’s 
pipelines of drug discovery, delivering new drug candidates at a faster pace and lower cost.
4-6
 
The current practical computational approaches for drug discovery are generally 
categorized into (but are not limited to) ligand- and structure-based.
2,7,8
 Ligand-based approaches 
rely on prior knowledge about what binds to the target. Such methods include pharmacophore 
recognition
9,10
 and quantitative structure-activity relationships
11,12
, which select the drug-like 
compounds according to the spatial arrangements and the descriptors based on the compound’s 








), but the limitations associated 
with the field are obvious: dependence on known binding modes, sensitivity to the alignment 
with known binding compounds, and poor predictions of binding affinity.
2
 In addition, it is rare 
that a compound obtained from an existing library (e.g. a hit or lead compound) becomes a drug 
without any modifications.
1
 In most cases, chemical alterations to various extents (lead 
optimization) are needed in order to improve the binding affinity and the bioavailability. In the 
absence of three-dimensional target structures, such modifications can hardly be designed 
precisely, so that extensive synthesis and experimental tests are still needed to confirm the 
discovery. 
In contrast to ligand-based approaches, structure-based ones consider the interactions 
between the small molecules (ligand) and the therapeutic target (receptor) explicitly, and 
determine the selection based on calculated affinity or selectivity.
15-17
 The most popular 
structure-based computational approach is molecular docking, which finds compounds that fit 
into the binding site with desired chemical properties and has been implemented in many 




). The major input needed for structure-based 
drug discovery is the three-dimensional structure of the biological target, while the structures of 
the drug candidates can simply be obtained from databases or constructed de novo. On one hand, 
independent of any known binding molecule or binding mode, a structure-based approach allows 
a more extensive search in the vast chemical space and has a potential of leading to novel 
candidates.
5
 On the other hand, structure-based approaches can also utilize the information from 
the known binding modes in order to narrow down the search and reduce the computational 
cost.
21
 Further, structure-based modeling is able to provide predictions of new binding modes, 
binding affinity, metabolites, etc.,
6,22




of the compounds. During recent years, there has been a growing effort to apply structure-based 
computational approaches to practical drug discovery. The development of such approaches 
highly benefits from the advances in functional genomics and proteomics as well as the 
increasing number of structures in the Protein Data Bank (PDB). For those targets without 
experimentally available structures, comparative modeling is applicable to building the atomic 
resolution model of the target from known templates of homologous proteins.
23-25
 The structure-
based computational approaches have already contributed to more than 50 new compounds, 
which entered into clinical trials.
1
 One of the major successful stories is the identification of 





Figure 1.1. An example of an HIV-1 protease inhibitor, whose development benefited from 
computational structure-based techniques. (A) HIV-1 protease inhibitor nelfinavir.  
(B) co-crystallized structure of HIV-1 protease with nelfinavir. (PDBID: 3EKX). 
 It is worth pointing out that the ligand- and structure-based approaches are often used in 
combination to solve practical problems. Synergies can be achieved easily by combining the 
strength of both approaches: the ligand-based approach can be applied to prioritize or filter 
compounds for further structure-based investigation; the structure-based approach can also 











Recently, there has been a growing interest in employing high-resolution target structures 
to accurately model ligand-receptor interactions, because the precise information about 
interactions such as solvation effects, hydrogen bonding, π-π interactions, and cation-π 
interactions are important in deciding the ligand orientations as well as the energetic and 
conformational changes during binding. Prior work includes identifying structural water and 
small molecule binding sites,
28
 computing binding affinity,
22
 predicting conformational changes 
upon binding,
29
 revealing conformational coupling in allosteric proteins,
30
 and studying 
interactions between proteins and other macromolecules.
31,32
 Based on the high-resolution target 
structures, the approaches are expected to accurately predict the binding mode and the binding 
affinity, which in turn requires leveraging the detailed information encoded in the structures and 
to accurately model the various energetic and conformational impacts. Ideally, such approaches 
are also expected to result in lower false positive rates (even lower false negative rates as well) 
as their resolution is high enough to distinguish subtle energetic and conformational changes. 
However, in spite of the recent success of computational structure-based drug discovery 
mentioned above, it is still very challenging to achieve accuracy sufficient to solve practical 
problems, mainly due to the scarcity of high-resolution target structures and the lack of accurate, 
efficient computational approaches at high resolution. Although modeling at Quantum 
Mechanics (QM) level is able to provide high accuracy, its computational cost is often 
overwhelming for macromolecules, especially due to the large number of conformations 
associated with each structure. Thus with regard to the current computational capacity, it is not a 




screening. As an alternative, force field methods at the all-atom level are able to consider many 
structures at a relatively low cost, but the accuracy highly varies from case to case. This calls for 
the development of robust force field approaches with high accuracy for structure-based drug 
discovery. 
Focusing on high-resolution modeling with force field methods, this dissertation 
describes research studies that develop accurate computational approaches for structure-based 
drug discovery. It covers the topics of target structure refinement and drug metabolite predictions, 
aiming to solve practical problems with high accuracy and efficiency. Since proteins represent 
around 90% of the current therapeutic targets, the focus of this dissertation is on proteins (as the 
typical targets), but we believe that our methodologies described herein are general, such that 
they can also be applied to other biomacromolecules. 
 The principle goal of structure-based drug discovery is to identify compounds with high 
binding affinities with the therapeutic target. As mentioned above, structures at atomic (or even 
sub-atomic) resolution are required in order to achieve this goal.
22
 However, most currently 
known macromolecular structures do not fulfill these high resolution requirements. While the 
majority (~90%) of the experimental structures in the PDB (www.rcsb.org) have resolutions 
poorer than 2.0 Å, many of the current comparative models do not even reach an accuracy of 
2.0 Å RMSD from the native structures, especially at low sequence identity (e.g. <30%).
33
 
Therefore, it is necessary to improve the low-resolution target models before they are used for 
tasks in drug discovery (such as virtual screening). Progressive computational refinement of the 
low resolution target structures represents a cost-effective and general solution to this problem, 
provided that accurate energy models and efficient sampling algorithms are available. To address 




model and efficient sampling algorithms for protein structure refinement. The VSGB 2.0 energy 
model includes specific terms to consider solvation effects, hydrogen bonding, π-π packing, and 
self-contacts, while our sampling algorithms employ a novel dipeptide library to improve the 
efficiency. Our new methodology has been rigorously tested on large data sets of protein single 
side chain (>2,000) and loop predictions (>100) and shows great potential to provide high-
resolution protein structures for structure-based drug discovery. 
 Apart from identifying drug-like compounds, it is also of great importance to predict the 
absorption, distribution, metabolism, excretion, and toxicity properties (ADMET) of these 
compounds.
6,34,35
 Accurately predicting the ADMET of drug candidates computationally helps to 
eliminate compounds with undesirable properties such as poor absorption and toxic side effects 
and therefore reduces the risks to fail in clinical trials. In particular, predicting the metabolites of 
drug candidates is crucial in improving the pharmacokinetics and in avoiding the toxicity 
associated with metabolites. It is believed that 12 enzymatic systems are involved in drug 
metabolism, among which the P450 system is the major one responsible for phase I 
biotransformation.
36
 So far, a number of P450 isoforms have been crystallized and their 
structures have been determined.
37
 These experimental structures provide an excellent starting 
point for developing structure-based approaches to predict the P450-mediated drug metabolism. 
Therefore, it is not surprising that predicting P450 metabolism has become a rapidly growing 
field.
38-40
 However, very few published methods and models can achieve both low false positive 
and low false negative rates in their predictions, and the inadequate accuracy of current methods 
has become a big challenge for practical use.
41
 Herein, a highly accurate computational approach, 
IDSite, based on the interactions of the substrates and P450 enzymes is developed in Chapter 3. 




protocol, which involves docking and refinement. The low false positive and false negative rates 
shown by tests of 56 compounds indicate the great potential of IDSite for practical drug 
discovery. 
In summary, all of the methodology presented in this dissertation is likely to enhance and 
streamline the process of lead generation and optimization, and provide in silico solutions to 
discover better drugs with high activity and good safety profiles. Further, the methodology can 
also be used to construct valuable tools to investigate the mechanism of action
42
 during target 




Chapter 2. Protein Side Chain and Loop Predictions 
2.1. Introduction 
Knowledge of protein structure at atomic resolution is essential for modeling biological 
function and structure-based drug discovery approaches.
43-45
 While the generation of 
experimental structures, propelled by high throughput crystallography,
46
 continues to advance 
exponentially, the number of known protein sequences is growing even more rapidly.
47
 
Furthermore, for any given sequence, there may be a significant number of biologically relevant 
conformations, not to mention possible structural reorganization associated with ligand binding 
or with protein-protein interactions. Hence, it is unlikely that the entire universe of biologically 
relevant protein structural data can be accessed by exclusively experimental means. 
Computational modeling represents the logical approach to constructing protein 
structures that are not experimentally available. The coverage of protein families continues to 
increase rapidly in PDB, which implies that the vast majority of protein structure prediction 
problems involve perturbation of a known structure by a relatively small RMSD. Homology 
modeling, using sequence and profile-based approaches,
25,48,491-3
 continues to make great 
progress, and models with the correct architecture and low RMSD can be built for substantial 
fraction of interesting cases, particularly for pharmaceutically relevant targets where substantial 




However, to predict relative protein conformation energetics and protein-ligand binding 
affinities, very high resolution structures are required, and current homology models are often 
not quite good enough for this purpose (although the suitability varies depending upon the target 
and the specific project for which the structure will be employed).
52




address this problem is refinement of homology models, in which the RMSD of the homology 
model is progressively reduced until it is suitably close to the native structure. Such a refinement 
strategy in turn requires a sufficiently accurate potential energy function, including modeling of 
solvation effects and detailed physical chemistry of protein interactions (e.g. hydrogen bonding). 
If the potential energy surface has a free energy minimum that is distinct from the native 
structure, this implies a fundamental limitation on the RMSD that can be achieved. With an 
accurate potential surface, one is then left with the problem of sufficiently robust and 
comprehensive sampling of phase space, a challenging task given that the homology model may 
deviate from the native structure at any location in the protein. 
There are various possible strategies that can be employed to carry out refinement. The 
most straightforward approach would be to perform a molecular dynamics simulation
53
 using an 
all-atom protein model and explicit representation of aqueous solvent.
54
 However, such 
simulations are very expensive computationally, and even assuming that the potential functions 
used in the simulation (which at present generally do not incorporate polarizability, for example) 
are adequate to yield the native structure as a free energy minimum, the effort required would be 
extremely large even for a small protein, and prohibitive for larger proteins and protein 
assemblies which constitute the great majority of biologically interesting systems.   
An alternative approach to refinement is to utilize a continuum representation of solvent, 
along with an all-atom protein force field. Continuum approaches have two major advantages. 
First, it is not necessary to average over the positions of explicit water molecules, which 
generally requires very lengthy convergence times.
55
 Secondly, conformational search methods, 
as opposed to molecular dynamics, can conveniently be employed in conjunction with a 
continuum solvation model.
56




than molecular dynamics for locating the global free energy minimum of the model, because 
much larger steps in phase space can be taken. The generalized Born continuum solvent 
model,
57,58
 in particular, is relatively inexpensive to evaluate, and is amenable to calculation of 
gradients, which are necessary for minimizations.   
While considerable progress has been made, in our group and others, in advancing the 
state of the art in continuum solvation calculations,
59-62
 two principal problems still remain. First, 
as in any energy model applied to high resolution protein structure refinement, the model must 
be accurate enough to actually improve homology models beyond their current level of 
resolution. In considering the accuracy of a force field plus a continuum solvation model, what 
matters is the potential energy surface defined by the model as a whole, as opposed to the 
individual components. The problem is in some ways more challenging than that of constructing 
force fields for explicit solvent simulation, because development of an accurate continuum 
model requires guessing and experimentation, since the functional form represents a reduction of 
the true Hamiltonian of the system to a non-rigorous model approximation (as is the case, for 
example, in density functional theory in electronic structure). Hence, the accuracy of continuum 
models requires continuous improvement, either by comparison with explicit solvent simulations, 
experimental data, or both. Secondly, the sampling problem remains one of great difficulty, 
although amenable to a wide range of algorithmic acceleration due to the ability to employ 
conformational search methods of various types. 
In previous studies of PLOP, a series of improvements in both the energy model and 
sampling algorithms have been implemented in the program.
63-70
 These improvements have 
enabled reasonable results to be obtained for loop predictions up to 20 residues. However, a non-




large energy errors (defined as the energy gap between the predicted and minimized native 
structures). These results, while encouraging, reflected the fact that there was still important 
missing physics in the previous energy models. 
In this chapter, a new energy model (VSGB 2.0) is described, which has been rigorously 
optimized by fitting to accurate experimental side chain and loop (11-13 residues) data, and 
contains a number of new terms not incorporated into the older functional form, as well as many 
re-optimized model parameters. The performance of the VSGB 2.0 model was evaluated by 
predicting structures for a set of 115 super long loops of 14-20 residues. At these lengths, 
alternative approaches in the literature uniformly display rapidly increasing RMSD errors,
71,72
 a 
reflection of the greatly expanded conformational freedom associated with these very long loops; 
and in fact, there are very few prior studies in which loops of such lengths have been investigated 
systematically using a large data set. Remarkably, despite the exceptionally demanding test set 
(for which no parameter adjustment was made to improve agreement with experiment), a high 
degree of robustness, and small backbone and side chain RMSD, are demonstrated for 100% of 
the test cases. Achieving this level of accuracy requires other improvements besides the energy 
model, most prominently continued advances in the sampling algorithms, and application of a 
reliable approach to assigning protonation states, both of which are described in what follows. 
Given the precision and uniform robustness of the calculations, it is believed that the VSGB 2.0 
model and sampling algorithms, for the first time, are suitable for successfully tackling the real 
problem defined above, refining homology models. 
Very different philosophies have been used over the past decade to optimize and to 
evaluate atomic level protein models based on continuum solvation description. Alternatives 




the PB model itself has to be parameterized in some fashion),
73,74
 exploring performance in the 
folding of small proteins,
75,76
 and comparisons with explicit solvent simulations.
54,77
 The present 
work is distinguished by the approach of fitting parameters to a large database of 
crystallographic single side chain and loop data (including a number of novel terms, one of 
which, the variable dielectric model, approximately incorporates polarization, and has proved to 
be extremely important in obtaining quantitatively useful results), and rigorously evaluating 
structural prediction accuracy for a large and demanding test set, the long loop data set described 
above. In our view, the use of these large training and test sets eliminates the possibility of 
overfitting, and provides confidence that the physics of the model is correct, and the right 
answers are being obtained for the right reason. 
This chapter is organized as follows. The selection of the training (side chain prediction, 
loop prediction) and test (super long loop prediction) sets is first discussed. It is shown that the 
use of an improved training set (as compared to that employed in ref.
68
) turns out to be very 
important; the training set from previous work, despite the overall structural accuracy implied by 
the crystallography, contained side chains with ambiguous atom placement due to missing 
electron density in the crystallographic data. Then briefly review of algorithms for side chain and 
loop prediction is provided.
63,64,66
 The VSGB 2.0 model is discussed in detail, as well as the 
optimization protocol based on single side chain and 11-13 residue loop predictions. Results for 
the test set of super long loop prediction (length of 14-20 residues) are then presented, along with 





2.2. Methods and Materials 
Selection of Data Sets 
The rapid increase in the number of high resolution X-ray crystallographic structures has 
allowed us to build reliable data sets for training and testing the VSGB 2.0 model. In order to 
ensure the high quality, the data sets were selected based on the following criteria: 
1. All structures are PDB X-ray crystallographic structures with low sequence identity (no 
more than 30% similarity) and high resolution (better than 1.0 Å for the side chain set 
and 2.0 Å for the loop sets). 
2.  Side chains or loops should not have alternative structures or missing heavy atoms. 
3.  Side chains or loops should not be affected by ligands. The distance between the side 
chain/loop and a ligand is defined as the shortest heavy atom distance. The minimum 
distance allowed to any organic ligands is 4.0 Å and to any metal ions is 6.5 Å. 
4.  The average B-factor should be lower than 35.00. 
5. The real space R-factor (RSR) of each residue should be lower than 0.200. 
6. All atoms of the side chains or loops should be found to occupy well defined peaks in the 
experimentally determined electron density when visualized. 
With all these criteria, 2239 single side chains from 45 proteins for the side chain training 
set, 100 loops (length of 11-13 residues) from 72 proteins for the loop training set, and 115 super 
long loops (length of 14-20 residues) from 97 proteins for the loop test set have been collected. 
 
Preparation of All-atom Models 
As most crystallographic structures do not contain the hydrogen positions, it is necessary 
to add hydrogen atoms and determine the protonation states of ionizable residues for calculations 




(due to the similar electron density of two alternative conformations rotated by 180°) also 
impairs the correct physics of the models. Therefore given the heavy-atom coordinates from X-
ray crystallography, all-atom models for each protein were created using the Interaction Cluster 
Decomposition Algorithm (ICDA).
67
 The ICDA assigns protonation states of ionizable residues, 
conformations of Asn, Gln, and His, and hydrogen positions of hydroxyls, by constructing 
clusters of potentially interacting side chains, enumerating a list of possible hydrogen bonding 
networks, and ranking these potential networks via energy evaluation. It is also worthy to 
mention that in this work the original ICDA algorithm reported in ref. 
67
 has been improved by 
using self-adjusted cluster sizes and more rigorous energy evaluation. 
In addition to the protein, crystal environment, organic ligands, and metal ions were also 
taken into account for a fair comparison to the crystal structures obtained from experiments. 
Since the role of crystal environment and ligands in protein structure prediction has been 
extensively discussed,
78
 their inclusion in our all-atom models was done in an automated fashion. 
 
Single Side Chain Prediction Algorithm 
Single Side Chain Prediction (SSCP) is defined as prediction of the conformation of one 
side chain with the rest of the protein fixed at the atomic positions of the native structure.
63,68
 The 
algorithm exhaustively samples side chain conformations with a residue-specific rotamer library 
at a high resolution.
79
 Clash-free conformations are evaluated and sorted according to the single 
point energy or the energy after minimization. The final prediction is determined by the lowest 
energy conformation, either with or without minimization. In this algorithm, all the 
conformations that remain after the steric clash check are kept for the evaluation stage. This is a 
modification to the original algorithm employed in previous publications, which prescreens all 




consider the cluster representatives. Since the total energy score is the only measure to evaluate 
all the conformations in the pool, the current version of SSCP algorithm is better able to provide 
a direct comparison of how well the energy models can distinguish the native from the non-
native conformations in realistic applications such as loop prediction, where all of 
conformational space is considered, and minimization of the loop (which includes all side chain 
degrees of freedom) is employed. The optimized parameters obtained from SSCP fitting are 
discussed below. 
 
Loop Prediction (11-13 residues) with Decoys 
Our loop prediction (length of 11-13 residues) was carried out with decoys generated 
from the loop predictions described in previous work.
66
 Each loop case contains thousands of 
conformations in the decoy set, representing a wide spread of samples in the conformational 
space. For the purpose of optimizing the energy model (more specifically the hydrophobic term), 
the minimized conformation with the lowest energy was selected as the prediction. Loop 
prediction of 11-13 residues was employed to optimize the hydrophobic term, because the 
hydrophobic term is much larger in a loop than in a side chain and thus more sensitive in loop 
prediction. The use of decoys avoids the costly sampling in a vast conformational space, greatly 
reduces the sampling cost, and consequently allows fast optimization of the hydrophobic term. 





Super Long Loop Prediction (14-20 residues) Algorithm 
Our algorithm of Super Long Loop Prediction (SLLP) uses a hierarchical approach 
combined with an advanced sampling method to predict loops longer than 13 residues.
64,66,80
 
Compared to the shorter loop prediction, super long loop prediction requires more intensive 
sampling efforts. To improve both accuracy and efficiency, the algorithm uses an advanced 
sampling method based on a detailed dipeptide backbone rotamer library, which was first 
described in previous work with 17% improvement in sampling efficiency.
80
  
In the SLLP algorithm, the loop candidates are first constructed without any constraint at 
the initial stage, while the rest of the protein remains the same as the native. An exhaustive 
search for possible loop conformations is carried out in one constrained refinement stages and a 
series of fixed stages. (Figure 2.1) At the end of each stage, the loop conformations generated in 
all the previously finished stages are ranked according to the energy after minimization, and the 
top ones without redundancy are sent to the next stage. Finally, the loop conformation with the 
lowest minimized energy is selected as the prediction.  
 
 
Figure 2.1. Hierarchical sampling of super long loop predictions. 
 
 
Each stage shown in Figure 2.1 contains multiple parallel single loop predictions, which 
build up the loop candidates, cluster them, and minimize and evaluate the centroid of each cluster. 
In this work, cis- rotamers are newly added to the dipeptide library originally described in ref. 
80
 




library depends on residue types and contains more information associated with the secondary 
structure. As different from many fragment assembly methods (e.g. the 3-residue and 9-residue 
fragments in Rosetta
81
), our dipeptide sampling is a unique method constructed from a large 
variety of high resolution protein crystallographic dataset. While a fragment in the fragment 
assembly methods are commonly used as a sliding window along a protein chain, our dipeptide 
sampling doesn’t use the rotamers in an overlapping fashion during a single loop prediction. 
Besides, each dipeptide rotamer only has 5 backbone dihedral angles (phi and psi angles of the 
two residues and the omega angle between them) for backbone sampling, but the 3-residue and 
9-residue fragments contains both backbone and side chain conformations for a quite different 
application in predicting small protein folding.  
To accurately predict protein loops longer than 13 residues, it is extremely important to 
generate conformations as close as possible to the native at the early sampling stages. During the 
initial stage, a large number of loop structures are constructed from 5 parallel calculations with 
overlap factor thresholds 0.45, 0.50, 0.55, 0.60, and 0.65. (In previous work, 0.55, 0.60, 0.65, 
0.70, and 0.75 were used.
80
) An overlap factor is defined as the ratio of distance between two 
atoms and the sum of their Van der Waals radii. Loop conformations are considered with clashes 
and then abandoned, if any pair of atoms is found with an overlap factor lower than the threshold. 
A high overlap factor threshold sometimes causes sampling failure in a confined space or 
generates similar loop candidates. Therefore, multiple low overlap factors in the initial stage are 
important to generate a wide variety of loop candidates for the later stages.  
The fixed stages, which sample a sub-region of the loop, are crucial in our hierarchical 
method for super long loop prediction. During the fixed stages, a large conformational space is 




candidates with the lowest energies. A “Fix N” stage (N=1, 2, 3…) only samples the residues that 
are outside of the fixed N residues in the loop. Since these N residues can start from either the C- 
or the N-terminus of the loop in question, all the N+1 combinations are considered in each “Fix 
N” stage. Sampling up to the “Fix 5” stage is adequate for the accurate prediction of many super 
long loops. However extending to the “Fix 10” stage successfully addressed several cases with 
serious sampling errors but also could lead to a relatively small number of cases with energy 
errors.  Results of long loop predictions are presented with sampling up to “Fix 5” for most of 
the cases except several cases sampled up to “Fix 10”.  Identified by the further test, the cases 
which have possible energy errors with sampling up to “Fix 10” are then discussed in the 
discussion section. 
 
Super Long Loop Prediction Method Incorporating Surrounding Side Chains 
To further test the effectiveness of the VSGB 2.0 model, super long loop prediction 
incorporating surrounding side chains (SLLP-SS) was performed. The method has been 
previously described by Sellers et al.,
70
 in which the surrounding side chains that have heavy 
atoms within 7.5 Å from any Cβ atoms in the target loop are optimized simultaneously with the 
loop. In SLLP-SS, these surrounding side chains are temporarily removed when the backbone of 
the loop is being sampled. Then the side chains on the loop as well as those in the surroundings 
are put back and optimized by rotamer library sampling and minimization. Because the 
conformational phase space increases substantially when the surrounding side chains are 
optimized in addition to the loop, our most extensive hierarchical approach for long loop 





The VSGB 2.0 Model 
Energy Function 
The VSGB 2.0 model provides a novel form of the energy function (Eq. 2.1) which 
contains the OPLS-AA protein force field
82
 bonded and nonbonded terms, as well as a solvation 
term and a number of physics-based correction terms. The solvation free energy Gsol and the 
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Solvation and desolvation effects are among the most important factors to determine a 
protein’s global and local conformations in solvent.83 The VSGB 2.0 model approximates the 
solvation free energy with an optimized implicit solvent model, which is based on Surface 
Generalized Born (SGB) model
57,58,60
 and the variable dielectric (VD) treatment of polarization 
from protein side chains.
68
 The SGB model, as an approximation to the Poisson-Boltzmann 
Equation (PBE), has been widely used in protein structure modeling. The variable dielectric 
treatment further improves the accuracy of the SGB model by varying the internal dielectric 
constants from 1.0 to 4.0 to incorporate the polarization effects. In this work the VD-SGB 
implicit solvent model, as an important component of the VSGB 2.0 model, has been further 
optimized via fitting to single side chain predictions. 
A typical GB model, the solvation free energy (Gsol) is expressed as the sum of a cavity 




sol cav vdw polG G G G                                                  (Eq. 2.2)
 
The nonpolar solvent-solute interaction is usually represented by the sum of the cavity term and 
the Van der Waals term, which is considered proportional to the solvent-accessible surface area 
(SASA) (Eq. 2.3). 
cav vdwG G SASA                                                   
   (Eq. 2.3) 
However, such a surface area model has been found insufficient to account for the nonpolar 
solvation effect (e.g. dispersion) in many previous studies. Therefore in our VSGB 2.0 model, 
the nonpolar contribution of solvation is calculated by a parameterized hydrophobic term 
described in detail below. The polar solvent-solute interaction is represented by the polarization 
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                                                    (Eq. 2.6) 
fGB is a function of the distances between two atoms (rij) and their generalized Born radii (αi and 
αj) of the form described in ref. 
68
. The internal dielectric constant εin (ij) can vary from 1.0 to 4.0 
as the maximum value of the internal dielectric constants of atom i and atom j. The Born alpha 
for the screen term is calculated as ij i j   . Table 2.1 shows the assignment of internal 





Table 2.1. Internal dielectric constants of the original and optimized VD-SGB model.
a
 
Residue Lys Glu Hip
b
 Asp Arg His
b
 Other 
Original VD-SGB Model 4.00 3.00 3.00 2.00 2.00 2.00 1.00 
Optimized VD-SGB Model 3.85 2.78 2.86 2.44 2.11 1.00 1.00 
a.
 The assignment of internal dielectric constants is based on an atom-based scheme: only the charged 
atoms and the atoms adjacent to the charged ones are assigned with values greater than 1.00. 
b.
 Hip: protonated histidine; His: neutral histidine. 
 
The optimized VD-SGB model reduces the values of internal dielectric constants for Lys, 
Glu, protonated His and neutral His while increases the values for Asp and Arg. These changes, 
although derived from parameterization, actually incorporate a better physical picture from two 
main aspects: first, the dielectric constant assigned to the neutral His is adjusted to be identical to 
other non-charged amino acid residues; second, the internal dielectric constants for the acidic 
amino acid residues (Asp and Glu) are tuned to have closer values, more consistent with their 
chemical similarity. 
 
Hydrogen Bonding Correction 
An accurate description of hydrogen bonds is critical to predicting protein structure at 
high resolution. While a conventional fixed charge force field such as OPLS-AA does a 
reasonable job of getting the magnitude of hydrogen bonding interactions right,
84
 it is limited by 
having an atomic point charge description of electrostatics, as opposed to a more accurate 
multipole or lone pair description. One approach would be to improve the electrostatics by 
explicit addition of such higher order terms, as has been done in the AMOEBA force field.
85
 An 
alternative is to use an empirical functional form to enforce hydrogen bond angles and distances, 
fitting to experimental PDB data. We have chosen to use the latter approach, following work of 
Baker and coworkers
86
 as in the spirit of exploiting the large amount of experimental structural 




new terms are added as a correction to the existing OPLS-AA force field and as part of the 
VSGB 2.0 model, and the parameters are optimized by fitting to improve single side chain 
prediction accuracy, as is discussed below. 
The hydrogen bonding correction EHB term is a function of distances, angles and atom 
types (Eq. 2.7). As the implicit solvent model is used, this correction is not applied to protein-
solvent hydrogen bonding, which can cause underestimation of the interaction between protein 
and the first-shell solvent.  






rE r                             (Eq. 2.7) 
where i and j are heavy atoms involved in a hydrogen bond. The parameters of hydrogen bonding 
geometry r0 (optimal distance between the hydrogen atom and the acceptor atom, 1.94Å) and θ0 
(optimal angle of the donor atom, the hydrogen atom and the acceptor atom, 160°) were adopted 
from the Density Functional Theory (DFT) optimized formamide dimer and acetamide dimer.
87
 
αi and αj are coefficients related to the roles of the heavy atoms playing in a hydrogen bond, one 
as a donor while the other as an acceptor. For an atom i, αi is assigned based on the following 
rules: 
1) Positively charged nitrogen atoms in the side chains of Lys, Arg, charged His, and the 
N-terminal backbone are strong donors, αi = 1.5. 
2) Negatively charged oxygen atoms in the side chains of Asp, Glu, and the C-terminal 
backbone are strong acceptor, αi = 1.5. 
3) Polar atoms in the side chains of Ser, Thr, Asn, Gln, neutral His, Tyr, and Trp can be 
either weak donors or acceptors. The assignment is dependent on the paired atom j: if 
atom j is a strong donor, atom i is a weak acceptor; if atom j is a strong acceptor and atom 




counted twice as a weak donor and a weak acceptor while atom j as a weak acceptor and 
a weak donor respectively (as long as both have hydrogen atoms). For the weak donor, αi 
= 0.5; for the weak acceptor, αi = 0.5. 
4) A neutral backbone oxygen atom is considered as a weak acceptor while a neutral 
backbone nitrogen atom is considered as a weak donor. 
The hydrogen bonding correction depends on the distance between hydrogen atom and 
the acceptor atom rHA, as well as the angles formed by donor atom, hydrogen atom and acceptor 
atom θDHA (Figure 2.2). Such a design involves the most relevant atoms in a hydrogen bond 
while being easy to implement and inexpensive to calculate. 
 
Figure 2.2. Geometry variables in hydrogen bonding correction. 
 
π-π Packing Correction 
π-π stacking is one of the main driving forces to stabilize vertical base stacks in DNA88,89 
and the hydrophobic cores in proteins.
90
 It also plays important chemical and biological roles in 
processes like self-assembly
91
 and molecular recognition.
92-94
 In contrast to covalent bonds and 
hydrogen bonds, π-π interactions are slightly directional with diverse preferred configurations, 
such as parallel stacking (sandwich and parallel-displace) and T-stacking (also known as 
T-shape),
93,95
 which are generally referred to as π-π packing interactions in this dissertation.  
However, it is difficult to rigorously separate packing interactions from other nonbonded 




the magnitude of the packing effects; observation of π-π interactions in native protein structures, 
via crystallography, and quantum chemical calculations of such interactions, using high level 
theories that adequately capture electron correlation effects. For example, Burly and Petsko 
found that the preferential distance for π-π packing interaction is 4.5~7.0 Å and the preferential 
dihedral angles are close to 90° in 34 protein crystallographic structures.
96
 An estimation of the 
free energy contribution from Burly and Petsko is between 0.6~1.3 kcal/mol. The quantum level 




Our own investigations involve an analysis of our side chain and loop data sets, and 
comparison of predicted and native structures using our previous energy model, which did not 
contain an explicit π-π packing term. When such a model is used, the native structures contain a 
systematically higher percentage of π-π interactions (estimated by geometrical criteria) than is 
seen in predicted structures. These observations have motivated the development of a stacking 
term, empirically optimized to reproduce side chain structures, and then tested via loop 
prediction.   
Given the insufficient treatment of π-π packing interaction in standard force field 
methods,
84
 it would be useful to design a new π-π packing correction to improve the accuracy of 
the previous energy model. Here, we present an explicit π-π packing correction in the VSGB 2.0 
model for pairs of amino acid side chains including the conventional aromatic ones such as Phe, 
Tyr, His and Trp as well as the Y-aromatic structures such as Arg,
92
 Asn and Gln. To reduce the 
complexity of the algorithm, only side chain-side chain packings are considered, although π-π 






Figure 2.3. Geometry variables in π-π packing correction. (A) T-stacking. (B) Parallel stacking. 
r1: distance between the centers in aromatic planes of two side chains; r2: horizontal 
displacement between the aromatic planes; r3: distance from the center in one aromatic plane to 
the other aromatic plane; θ: dihedral angle between the aromatic planes (0°~90°).  
 
In Eq. 2.8, the π-π packing correction is expressed as a function of distances r1, r2, and r3 as well 
as dihedral angle θ (Figure 2.3). 
       1 2 3packingE f r f r r fC f                                (Eq. 2.8) 
     0 1exp expf A B x xx x x                                   (Eq. 2.9)                
f(x) is a normalized continuous function which shape is similar to a step function. In Eq. 2.9, 
coefficients A and B are constants with values 2.0, while x0 and x1 represent the boundaries for 
the variable x which values are shown in Table 2.2. The coefficient C for the packing correction 
is 3.0 kcal/mol, which is in the range of Jurecka’s estimation. 
 
Table 2.2. Geometry parameters for π-π packing correction. 
 r1 (Å) r2 (Å) r3 (Å) θ  (°) 
x0 3.5 0.0 0.0 0.0 (θ < 45°), 80.0 (θ >= 45°) 






It is common in proteins to find side chains of Asn, Gln, Ser, and Thr interacting with 
their own backbone nitrogen or oxygen atoms. Such an interaction depends on both the side 
chain conformation and the secondary structure, so that it is more complicated than a normal 
hydrogen bond. It was found by Pal et al. that self-contact interactions have specific roles in 
protein local environments,
98
 while most of them have tertiary interactions, saturated by 
hydrogen bonds from side chain-backbone and side chain-solvent. Therefore, self-contact 
interactions are considered as a special case of hydrogen bonding in the VSGB 2.0 model.  
The correction is represented as a sum of Gaussian functions dependent on the distance r 
between two heavy atoms with self-contact interactions (Eq. 2.10).  
2
0exp[ ( ) ]self contactE A B r r C                                    (Eq. 2.10) 
One atom is the polar atom from the side chain of Asn, Gln, Ser, or Thr, while the other one is 
the backbone nitrogen or oxygen atom in the same residue. Based on our statistical study with 
high resolution PDB structures, Asn, Ser, and Thr are most likely to form self-contact 
interactions, so that the correction is stronger for these three amino acid residues. The value of r0 
was taken from the most populated distance for the corresponding amino acid residue. Ser and 
Thr are treated with identical parameters due to their similarity in side chain hydroxyl group. It is 
worth mentioning here that the coefficient C is used to rescale the correction if the amino acid 
residue is in a regular secondary structure, since the self-contact interaction disturbs the 
hydrogen bonding network in a helix or sheet. Parameters for the self-contact correction are 






Table 2.3. Parameters of self-contact correction. 
 Asn Gln Ser, Thr 
A (kcal/mol) -4.7 -2.5 -4.8 
B 3.2 4.0 3.2 
C 1.0 0.0 0.8 
r0 (Å) 3.2 3.8 3.2 
 
Hydrophobic Term 
The hydrophobic term was introduced by us in a previous version of our energy model. 
The original term was taken from a scoring function employed in docking calculations, 
ChemScore.
66,99
 The hydrophobic term rewards contacts between nonpolar heavy atoms and 
stabilizes hydrophobic contacts. As the effect of hydrophobic term is much smaller in one side 
chain than in a loop, in the VSGB 2.0 model we replaced the linear function with a polynomial 
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  2.0 ( 2.0) / 3.0vdw vdwij i jscale r r r                                (Eq. 2.13) 
The coefficient in Eq. 2.11 was fit by a line search algorithm and the optimal value we obtained 
is 0.30. (Comparison of the linear function and polynomial is shown in Figure 2.10 in appendix.) 
 The hydrophobic term is intended to model the interaction of hydrophobic surfaces 
presented by various protein and ligand groups with water; when these groups make contacts (in 
the extreme case forming the hydrophobic core of the protein), unfavorable interactions with 
water are eliminated, and this effect drives hydrophobic packing. The atom-atom contact term 




and Van der Waals interactions of the solute atoms with the solvent. Our empirical investigations, 
initially described in ref. 
66
 but continued over the past several years with extensive experiments 
on large data sets, suggest that the model of Eq. 2.12 and 2.13 provides superior predictions as 
compared to more standard approaches penalizing exposed hydrophobic surface area, which are 
generally derived from small molecules in bulk solution, a very different situation from 
hydrophobic groups embedded in an active site cavity, or otherwise positioned in confined 
spaces within a protein environment. Therefore, in the VSGB 2.0 model, we have eliminated the 
Gcav and Gvdw terms discussed above in Eq. 2.2 and 2.3, and replaced them with the hydrophobic 
term presented in this section. The quality of results for long loop prediction, which involve no 
further adjustment of the energy model, will serve as an unbiased test of the validity of this 
approach. 
 
Optimization of the VSGB 2.0 Model 
In the development of the VSGB 2.0 model, we fit the methods and parameters to 2239 
single side chain and 100 11-13 residue loop predictions. The goal of optimizing the parameters 
in the VSGB 2.0 model was not only to improve the results of single side chain or loop 
prediction, but also to give a more accurate physical description that is transferable to tackle 
practical problems such as homology model refinement. As mentioned in the introduction, fitting 
to large high-quality experimental data sets helps to capture the correct physics in proteins and 
reduces the risks of overfitting. 
The VSGB 2.0 model was optimized by carrying out single side chain prediction. As 
mentioned previously, the prediction of a single protein side chain can be determined by the 
lowest energy conformation either without minimization (single point) or with minimization. We 




minimization selection during the procedure to optimize our model. Thus the parameter 
optimization is based on the ability to select the lowest energy structure, as well as the ability to 
make a good approximation of the energy funnel. Except the hydrophobic term which was fit to 
11-13 residue loop predictions with decoys, all the parameters of the solvent model and physics-
based corrections were optimized by a script based on a Monte-Carlo (MC) algorithm. The MC 
script generates parameters, recalculates the single point energy for each side chain candidate in 
the pool, and determines the prediction by the lowest energy candidate. We selected two sets of 
optimal parameters with the lowest average RMSDs suggested by the MC script, and performed 
the actual side chain predictions to determine the final parameters as the ones leading to the 
highest success rate with and without minimization.  
 
2.3. Results 
Single Side Chain and Loop (11-13 residues) Prediction 
The results of single side chain prediction obtained by the VSGB 2.0 model are shown in 
Table 2.4 in comparison to our previous energy model (herein referred to as VSGB 1.0), which 
employs the OPLS-AA energy function with the original variable dielectric solvent model and 
the earlier implementation of the hydrophobic term. 11 polar or charged amino acids were 
included for the fitting in order to compare to the results from previous work. The overall 
accuracy of the 2239 single side chain predictions is as high as 93.0% with single point energy 
evaluation (SP) and 91.6% with minimized energy evaluation (MIN) respectively. Generally the 
VSGB 2.0 model improves the prediction accuracy for 1.0% (SP) and 2.0% (MIN). The most 
significant improvements come from Gln and Asn, at 3.1% (SP), 5.6% (MIN) and 2.0% (SP), 3.2% 
(MIN). Another remarkable improvement advanced by the VSGB 2.0 model is to reduce the 




evaluation. With the VSGB 1.0 model, the difference in success rate is 7.5% for Lys and 8.1% 
for Gln; with the VSGB 2.0 model, it is reduced to 1.6% and 5.6% respectively. Given the high 
success rate of the VSGB 1.0 model, such an improvement is non-trivial. It is evident that the 
VSGB 2.0 model improves not only the energy score but also the gradient of the energy score.  
 
Table 2.4. Summary of single side chain prediction results for 11 polar or charged residues. 

























Arg 144 85.4 84.0  83.3 82.6  171 77.8 
Asn 252 92.5 91.7  90.5 88.5  237 85.7 
Asp 293 94.9 94.9  94.2 92.5  254 91.7 
Cys 92 100.0 100.0  100.0 100.0  49 93.9 
Gln 161 88.8 83.2  85.7 77.6  161 85.7 
Glu 152 88.8 86.2  88.2 84.9  193 79.3 
His 83 95.2 95.2  91.6 91.6  132 86.4 
Lys 121 91.7 90.1  95.9 88.4  198 76.8 
Thr 404 95.8 94.3  94.8 92.6  302 92.4 
Tyr 221 99.5 99.1  99.1 98.6  184 89.7 
Ser 316 88.9 88.0  88.3 86.1  297 79.1 
All 2239 93.0 91.6  92.0 89.6  2178 85.0 
All the single side chain predictions were performed with ICDA prepared structures. 
a
 A “successful” prediction is defined as one where the heavy atom RMSD < 1.5 Å to the native side chain 
conformation. The percentages reported in here are the ratio of the number of accurate predictions to the 
total number of predictions. “SP” stands for the single point energy evaluation; “MIN” stands for the 
minimized energy evaluation.  
b 
This method uses the original single side chain prediction algorithm, a different data set and the VSGB 





 The hydrophobic term was optimized with loop predictions of 11-13 residue length, 
results of which are presented in Table 2.5. Although the change from linear form to polynomial 
form did not significantly improve the accuracy, we still believe that the basic physical 
arguments can easily justify our reformulation, which here allows for the introduction of a 




particular, a continuous first derivative would take the force into consideration and allow a 
smoother minimization. Likewise, to our knowledge, there is no experimental evidence to 
suggest that the hydrophobic forces exerted between crystal mates should be any different than 
those hydrophobic forces exerted within the unit cell. Thus, the parsimony principle seems to 
motivate the change, even in the absence of strong data suggesting the polynomial form adopted 
here is fundamentally more accurate than the earlier linear ramping function.  
 
Table 2.5. Summary of 11-13 residue loop prediction results with different forms of 
hydrophobic term. 
Hydrophobic term 





Linear No 0.81 91.0 
Polynomial No 0.83 91.0 
Polynomial Yes 0.85 91.0 
 
It should be noted that the average RMSD of ~0.8 Å reported in Table 2.5 arises from 
selection of loops from a suite of decoys generated with an older energy model from ref. 
66
, as 
opposed to full scale optimization of loop prediction with the current energy model and sampling 
algorithms. In view of the results to be reported below for longer loops, it is likely that improved 
results would be obtained for 11-13 residues loops with the latter, more rigorous sampling 
protocol. 
 
Super Long Loop (14-20 residues) Prediction 
In order to validate the effectiveness of the VSGB 2.0 model, a super long loop set was 
used to test the accuracy of the energy function described herein. A summary of the results is 





Table 2.6. Summary of super long loop prediction results. 











































14 36 0.38 0.51 1.67 100.0  0.67 1.19 2.51 91.7 
15 30 0.54 0.63 1.85 100.0  0.75 1.55 3.07 73.3 
16 14 0.43 0.70 1.85 100.0  0.80 1.43 3.20 78.6 
17 9 0.57 0.62 1.84 100.0  1.92 2.30 4.25 66.7 
18 16 0.60 0.80 1.78 100.0  3.45 4.18 5.59 37.5 
19 7 1.60 1.41 3.46 100.0  1.31 2.65 3.87 57.1 
20 3 1.68 1.59 2.88 100.0  1.12 1.43 2.71 66.7 
All 115 0.52 0.69 1.91 100.0  1.04 1.89 3.37 73.0 
RMSD calculation: A predicted structure is superimposed to the native protein structure excluding the 
target loop. Backbone RMSDs are calculated with N, Ca and C atoms; side chain RMSDs are calculated 




Figure 2.4. Accuracy of super long loop predictions. Red dots represent the average backbone 
RMSDs while green lines represent the ranges of the backbone RMSD. 
 
Testing on the same data set, we are able to make a direct comparison of the relative 
performance of the VSGB 2.0 model and the VSGB 1.0 model. Using the VSGB 2.0 model, 




where only 73.0% of the predictions made with the VSGB 1.0 model would be similarly accurate. 
Furthermore, the better performance of the VSGB 2.0 model was independent of any particular 
chosen success criteria, as depicted by Figure 2.5, where the percentage of predicted loops with 
RMSD lower than a cutoff is plotted as a function of the given cutoff. The prediction difficulty 
often increases dramatically with loop length; however, our results with the VSGB 2.0 model 
reflect average backbone RMSDs in a narrow range from 0.51 to 0.80 Å for 14-18 residue loops. 
Even though it is extremely challenging to predict loops longer than 18 residues, the VSGB 2.0 
model still displays high accuracy with average backbone RMSDs of only 1.41 Å and 1.59 Å for 
19 and 20 residue loops. Apart from the backbone, the VSGB 2.0 model also significantly 
reduces the RMSDs for side chains in the loops. For example, for 18 residue loops, we obtained 
average backbone/side chain RMSDs of prediction are 0.80/1.78Å with the VSGB 2.0 model 
compared to 4.18/5.59Å with the VSGB 1.0 model. 
 
Figure 2.5. Comparison of loop prediction results using the VSGB 1.0 and 2.0 models. The y-





For super long loop prediction, the hierarchical algorithm is able to enrich the native-like 
conformations along the increasing fixed stages. The analysis of the average RMSDs at each 
stage shows that the VSGB 2.0 model not only provides an accurate score for the final prediction, 
but also improves the accuracy for each prediction stage (Figure 2.6), allowing higher percentage 
of native-like confirmations and faster convergence towards the global minimum. For example, 
both 14 and 15 residue loop predictions reach average RMSD below 2.0 Å at least one stage 
earlier with the VSGB 2.0 model. This also implies that fewer sampling stages are required with 
the VSGB 2.0 model, making the loop predictions more cost efficient. 
 
Figure 2.6. Average backbone RMSD of the predicted 14 and 15 residue loops at each stage. 
 
Super Long Loop (14-20 residues) Predictions in Inexact Environments 
A subset of 10 cases ranging from 14 to 16 residues (all with reliable well resolved 
electron densities for the target loop as well as surrounding side chains) were used to test loop 
predictions in inexact protein environments. An inexact environment was here created by 




new structure with surrounding side chains. The loop prediction in inexact environments was 
performed with method SLLP-SS, as was described earlier in Methods and Materials section. 
The test results are shown in Table 2.7. 
 



































1E6U A274 14 28 0.00 0.27 0.85 3.37 0.31 1.07 
1ZEQ X53 14 61 0.00 0.21 2.10 3.52 0.28 2.08 
2BWR A269 14 69 0.00 0.31 1.70 3.35 0.58 2.64 
3BY9 A205 14 59 0.00 0.32 0.81 3.14 0.41 0.83 
3EHR A95 14 83 0.00 0.51 3.40 4.09 1.30 4.08 
1QAZ A298 15 51 0.00 0.99 3.00 3.46 2.18 4.52 
1RA0 A283 15 36 0.00 0.30 2.13 6.51 1.24 2.38 
1RA0 A361 15 81 0.00 0.52 1.66 5.10 0.52 1.70 
3CSS A95 15 52 0.00 0.52 1.39 3.06 1.98 3.62 
1WM3 A67 16 49 0.00 0.23 1.24 3.08 0.26 1.63 
Average RMSD 
  
 0.42 1.83  0.91 2.47 
The RMSD of a starting structure was calculated as the backbone RMSD of the target loop in the starting 




Compared to the starting structures, all the 10 cases display improvements in RMSDs 
after the loop reconstruction. This confirms that the VSGB 2.0 model together with the 
augmented sampling method presented herein is able to improve the quality of models, 
suggesting a high potential to succeed in refining comparative models. Although starting from 
the inexact environment degrades the overall performance by 0.49 Å in the backbone RMSD, 
many of the cases actually reach similar accuracy as starting from the exact environment, such as 
1ZEQ X53-66 and 3BY9 A205-218. Furthermore, the average error is still a highly satisfactory 





The single side chain prediction results represent a major advance as compared to the 
accuracy levels reported in ref. 
68
. A great deal of the improvement is due to the use of a better 
side chain data set (in which all of the atoms in the side chain are reliably located by from the 
electron density obtained from the crystallographic observations), as opposed to improvements in 
the energy model. These results demonstrate that data set quality is vital in both development and 
assessment of molecular models. Problems with the data set will invariably produce misleading 
(and in some cases highly misleading) conclusions with regard to the performance of the model. 
The improvements in accuracy attributable to the new model are relatively small, but 
significant, particularly as they are clustered in the polar and charged side chains. Furthermore 
the vast majority of cases, where predictions failed, have quite small energy gaps, implying that 
the impact on loop prediction of such errors would be relatively minimal. However, we note that 
elimination of erroneous predictions is not the only benefit to adding a new, physically important 
term to the energy model. In many cases, the VSGB 1.0 model may have given a correct 
prediction for a particular side chain, but not properly evaluated the energy of the side chain 
conformation as compared to possible alternatives. As an example, consider the π-π packing term 
which rewards stacking of aromatic residues. In many cases, these residues are in the 
hydrophobic core of the protein, and re-prediction of the side chain conformation of the residue 
can have only one outcome due to steric considerations; the problem is like a jigsaw puzzle in 
which the “piece” can fit back into the puzzle in only one “conformation”. However, the energy 
gained from forming the entire core in the specific fashion that enables many stacking 
interactions to be formed may be underestimated by an energy model that does not reward 
stacking interactions. This would have consequences not only for loop prediction (where, as we 




the native conformation) but also for refining a homology model so that it has the optimal 
interlocking pattern of side chain interactions. Optimization of the π-π stacking and other terms 
to improve side chain prediction uses a small fraction of “sensitive” side chain cases to detect 
problems in the energy model and optimize the terms that improve these cases. The success of 
this strategy is manifest in the results reported above for long loop prediction, where very large 
improvements in average backbone RMSD and associated average side chain RMSD are seen 
uniformly for the 14-20 residue loop database. The VSGB 2.0 model fixes a number of cases 
which previously had substantial energy errors leading to inaccurate loop RMSDs. 
 
Computational Cost of Single Side Chain and Super Long Loop Predictions 
 One single side chain prediction (without clustering) usually takes from a few seconds 
(e.g. for His and Cys which have only a few rotamers) to 1 hour (e.g. for Lys and Arg which have 
thousands of rotamers) with a single 2.66G Hz Intel Xeon processor. With the same architecture, 
the average time needed in super long loop prediction for the stage of initialization, the stage of 
refinement, and one stage of fix sampling  is 10, 30, and 100 hours respectively. Since all the 
calculations in one stage can be carried out in parallel, a full loop prediction with sampling up to 
“Fix 5” takes around 1 day to finish with 20 processors. 
 
Importance of Systematic Application of Protonation State Assignment 
 When making either single side chain predictions or loop predictions, it is extremely 
difficult to achieve accurate predictions if one or more ionizable side chains are represented in 
the incorrect protonation state. As a simple example, some Asp and Glu residues form 
carboxylate “dimers” with neighboring Asp or Glu residues without any nearby metal ions; in the 




observed to be within hydrogen bonding distance (~3.0 Å). This type of structure implies that at 
least one of the carboxylates must be protonated. This costs free energy with regard to the 
standard protonation state of a carboxylate in solution, but is clearly necessary to avoid large 
repulsive interactions between charged oxygen atoms that would otherwise occur (vs. forming a 
strong hydrogen bond). If the unprotonated forms are used, the “dimer” structure will never be 
predicted as lowest in energy. Loop prediction is more subtle, but side chains in loops do form 
salt bridges and hydrogen bonds which are dependent upon protonation state. If these 
interactions cannot be formed due to failure to incorporate a nonstandard (but accessible) 
protonation state, the energy of the native loop conformation may fail to be competitive with 
incorrect alternatives.   
 All of the loop and side chain prediction results shown below have been generated by 
running an automated protonation state assignment program, the ICDA, based on methods 
described in ref. 
67
, on the entire protein of each member of the test set. Since the publication of 
ref. 
67
, we have put significant efforts into improving the ICDA by running a large number of test 
cases and examining them visually to make sure that obvious errors are eliminated. However, the 
data sets in the present paper have been treated in an automated fashion. The effects on accuracy 
of failing to run the ICDA has been examined for a selected set of loops, those which yielded 
large energy errors in previous work which did not employ systematic ICDA preparation (but 
also used a different energy model). By rerunning these cases with ICDA preparation and the 
VSGB 1.0 model, it is possible to identify a subset of cases where ICDA preparation is essential 
to achieving accurate results. At least 8 of 115 cases (7.0 %) require ICDA preparation to achieve 











VSGB 2.0,  
with ICDA 
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1RA0 A283 15 7 0.30  0 1.03  -39 2.78 
2PKF A26 15 0 0.65  10 0.47  -8 2.34 
2BG1 A708 16 -3 0.40  5 0.59  -4 2.15 
2PYW A321 16 -1 0.99  -5 0.72  -37 2.57 
2HDW A131 17 10 0.60  -3 0.42  -126 2.22 
3CUZ A384 18 4 0.82  -4 0.70  -22 3.45 
3EH1 A813 18 11 1.60  5 1.54  -22 2.84 
3GGQ A550 18 8 0.37  8 0.53  -26 5.12 
EGAP: energy of the prediction – energy of the minimized native structure. 
 
 In the present work, we are able to assign protonation states with high accuracy due to 
having the native structure available. In the context of realistic homology model refinement, the 
native structure would not be known in advance. Achieving the correct protonation states would 
then require sampling differing protonation states on the fly during the simulations, and/or 
running a number of alternative protonation states as a part of the iterative refinement algorithm 
protocol.  
 One interesting test towards the development of on-the-fly protonation state sampling 
algorithm is to predict the pH-dependent conformational changes. One good example is the 
bovine β-lactoglobulin, which X-ray crystallography has distinguished its different 
conformations of loop 85-90 at pH 6.2 and 8.2.
100
 A preliminary test showed that at different 
assigned pH values, ICDA correctly assigned the protonation states of Glu89 which is buried at 
pH 6.2 (protonated, PDBID: 3BLG) and exposed to solvent at pH 8.2 (deprotonated, PDBID: 
2BLG). With the correct protonation state assignment, our loop prediction had a good agreement 




8.2). (Figure 2.7) This test has indicated the capability of ICDA in correctly predicting the 
protonation states with different conformations, and can be interpreted as a progress in the 
development of on-the-fly protonation state assignment. 
 
Figure 2.7. Overlay of loop predictions (loop A84-91) at pH 6.2 and 8.2 to their corresponding 
native structures for bovine β-lactoglobin. At pH=6.2, prediction (green, backbone 
RMSD=1.3 Å) and native (blue, PDBID: 3BLG); at pH=8.2, prediction (red, backbone 
RMSD=0.7 Å) and native (yellow, PDBID: 2BLG). 
Further, a number of publications in the literature describe successful on-the-fly 
protonation state sampling algorithms, which could be adapted to our refinement algorithms. It is 
likely though that a significant effort will have to be put into making sure that, these methods are 
sufficiently accurate to reliably achieve refinement objectives. The results presented in this 
dissertation should be viewed as proof of concept, demonstrating that if accurate protonation 
states can be assigned, significant improvement in blind structural prediction efforts will result. 
Running tests without proper protonation states, in contrast, would make it impossible to 





A Better Description of Protein Energy Landscape 
As a mini folding problem, super long loop prediction at high resolution demands an 
energy model with highly precise physical description of the loop in question as well as of the 
environment. However, an inaccurate energy model with missing physics usually fails to 
discriminate the native conformations from the non-native ones, leading to wasted sampling 
effort in the false global minimum which could be far away from the true one. This explains why 
sometimes a more intensive sampling effort leads to a poorer prediction. Through our analysis of 
such mispredictions, the missing physics in our previous energy models appeared to be stemming 
from inaccurate descriptions of electrostatic, hydrogen-bonding, hydrophobic, and π-π 
interactions..
 
Figure 2.8. Overlay of 6 predicted loops using VSGB 1.0 (red) and VSGB 2.0 (green) models to 





Using the optimized variable dielectric solvent treatment and the additional physics-based 
corrections, the VSGB 2.0 model is likely to provide a better, more complete physical 
description for protein high resolution modeling. The addition of corrections, especially to the 
hydrogen bonding, π-π interactions and hydrophobic interactions, compensates the effects that 
were incompletely described by the electrostatics, Van der Waals, and nonpolar interactions in 
the VSGB 1.0 model. As a result, the corresponding native or native-like conformations are 
stabilized, with respect to the competing non-native conformations, and thus are more likely to 
be the global minimum energy structure on the potential energy surface. In addition to the more 
accurate description of the global minimum energy structure, the VSGB 2.0 model also 
incorporates a stronger bias along the whole of the energy surface towards more native-like 
conformations, which could be due to the improved physical description of the overall energy 
surface. One indication of the greater bias of potential energy surface of the new energy function 
towards more native like structures is shown in Figure 2.8, where the VSGB 2.0 model gives 
lower average backbone RMSDs for each stage compared to the VSGB 1.0 model. This 
indication could be interpreted as preliminary evidence that the new energy function is better 
describing the “folding funnel” of the protein potential energy surface.101,102 Another indication, 
more direct, is the consistent correlations of relative energies and RMSDs considering all the 
conformations that have been sampled during the loop prediction. An example is presented in 
Figure 2.9 to further demonstrate the better physical description in the VSGB 2.0 model using 





Figure 2.9. Loop prediction results with serious energy error in the VSGB 1.0 model fixed by 
VSGB 2.0 model. (A): overlay of the native (yellow) structure and the prediction using 
VSGB 1.0 (red) and VSGB 2.0 (green) models.PDBID: 1UW4. Loop B899-916: backbone 
RMSD =2.0 Å, EGAP=5 kcal/mol (VSGB 2.0); backbone RMSD=11.3 Å, EGAP=102 kcal/mol 
(VSGB 1.0). (B): relative energies (VSGB 2.0: green; VSGB 1.0: red) versus backbone RMSDs. 
 
Water between Protein Molecules in Crystal Structure 
The 14 residue loop (A153-166) in a nucleotidase (PDBID: 1JP4) is unique in our data 
set of super long loops: at the beginning, neither the VSGB 1.0 nor the VSGB 2.0 model alone 
gave reasonable predictions. (The VSGB 1.0 model: backbone RMSD=7.26 Å, EGAP=43 
kcal/mol; the VSGB 2.0 model: backbone RMSD=2.40 Å, EGAP=30 kcal/mol). Considering our 
starting point of improving the physical description, what is the missing physics in this case? An 
analysis of the native structure has shown that the water molecules bridge the loop in question 
and the crystal environment, which could lead to the incorrect energy evaluation due to the 
limitations of the implicit solvent model.  
The sequence of this 14 residue loop (PYYNYQAGPDAVLG) has a high fraction of non 
charged residues, which in this case have strong hydrophobic interactions, unusually, 





with the hydrophobic core of the protein molecule which the loop is a part of. Instead of forming 
the extended native conformation which contacts the neighboring proteins, all the mispredictions 
are packed into the protein body. However, we found that there are three bound water molecules 
(HOH 858, 1057, and 1083) which contribute significantly to the stability of the extended native 
conformation: all these water molecules connect the loop to the crystal environment through 
their hydrogen bonding network and consequently pin down the extended conformation 
(Figure 2.10). Such a first-shell solvation effect is unlikely to be well represented by any implicit 
solvent model, and thus we could not create the correct physical environment unless these water 
molecules were included. 
In order to repredict this loop in the correct physical environment, we explicitly added 
these three water molecules and the ones that form hydrogen bonds with them (HOH 858, 911, 
1057, 1083, 1108, 1145, and 1173) to our all-atom model. Hydrogen bonds between the explicit 
water molecules and the proteins were considered. With the presence of these water molecules 
and the hydrogen bonding correction applied to protein-water interactions, the prediction with 
the VSGB 2.0 model yields high accuracy (backbone RMSD=0.31 Å, side chain RMSD=0.67 Å, 
EGAP=4 kcal/mol). This case study highlights the limitations of implicit solvent models, and 
suggests possible treatments of including or predicting crystal water positions in future works. 
It should be noted that the explicit waters are required specifically in the interstitial 
region between protein molecules in the crystal structure. For a single protein molecule in 
solution, the loop in question would in fact almost certainly adopt a different conformation, since 
the hydrophobic region of the loop is buried in a hydrophobic region of the neighboring protein 




without the crystal waters, in which the hydrophobic interactions of the loop are primarily 
intramolecular, as opposed to with the neighboring molecule in the crystal.   
 
 
Figure 2.10. The 14 residue loop in a nucleotidase (PBDID: 1JP4. Loop A153-166) and bound 
crystal water molecules. Protein molecules from the crystal environment are shown in line 
representation with green or yellow carbons. Bridging water molecules are shown in red spheres. 
 
Possible Energy Errors in Current Data Set 
 The simulation of 115 long loops carried out in this paper requires a substantial amount 
of computation time. Furthermore, the lengthiest simulations (using 10 fixed stages, referred to 
in the text as “Fix 10”) requires considerably more computational effort than the 5 fixed stage 
(“Fix 5”) algorithm that was employed for most of the calculations. This is the reason that in the 
data set presented above we utilized the “Fix 10” algorithm only in cases where the “Fix 5” 




 However, it must be recognized that such a protocol could conceivably lead to bias in the 
results, as we do not know whether running the full “Fix 10” protocol on all of the cases would 
produce additional errors. We have carried out an assessment of this problem, and cases 
identified with energy errors using “Fix 10” sampling are listed in Table 2.9. 
 
Table 2.9. Cases with energy error from “Fix 10” sampling. 
   














1N0Q A24 14 -12 0.51  -18 3.62 
1RA0 A361 15 -5 0.52  -9 3.47 
3CSS A95 15 -17 0.52  -24 2.77 
2PYW A321 16 -1 0.99  -10 4.45 
3CUZ A384 18 4 0.82  -11 2.77 




In this work, we have described a new energy model (VSGB 2.0) which contains an 
optimized solvent model and physics-based correction terms. The VSGB 2.0 model was fit to a 
large database of protein single side chain and loop (11-13 residues) prediction and validated by 
a large set of super long loop predictions. It was shown that the VSGB 2.0 model, combined with 
the systematic protonation state assignment, improved the accuracy of super long loop 
predictions by 27.0% compared to our previous energy model (VSGB 1.0). A series of extensive 
analysis shows that the VSGB 2.0 model not only improved the results of single side chain and 
loop predictions, but also provides a better physical description for high resolution protein 
structure modeling. Further tests will include receptor-ligand docking, longer loop prediction, 
loop-helix-loop prediction, and applications on a variety of proteins, such as kinases, G protein-




2.6. Appendix for Chapter 2 
Table 2.10. Proteins in the single side chain set. 
No. PDB ID Resolution (Å) pH Length (residues) 
1 1A6M 1.00 7.0 151 
2 1BYI 0.97 6.5 224 
3 1C7K 1.00 7.0 132 
4 1EB6 1.00 7.5 177 
5 1G6X 0.86 7.5 58 
6 1GQV 0.98 6.5 135 
7 1IQZ 0.92 6.5 81 
8 1L9L 0.92 7.0 74 
9 1LNI 1.00 7.2 96 
10 1MN8 1.00 7.5 100 
11 1MUW 0.86 7.5 386 
12 1N1P 0.95 7.4 504 
13 1NKI 0.95 7.0 135 
14 1NLS 0.94 6.8 237 
15 1NWZ 0.82 7.0 125 
16 1OAI 1.00 6.5 68 
17 1PJX 0.85 6.5 314 
18 1R6J 0.73 7.0 82 
19 1SSX 0.83 8.0 198 
20 1UFY 0.96 7.0 122 
21 1UG6 0.99 7.4 431 
22 1VYR 0.90 6.2 364 
23 1W0N 0.80 6.5 131 
24 1X8P 0.85 7.4 184 
25 1ZLB 0.97 8.0 122 
26 1ZZK 0.95 8.0 82 
27 2A6Z 1.00 6.3 222 
28 2B97 0.75 7.3 71 
29 2BF6 0.97 7.0 449 
30 2FOU 0.99 7.7 260 
31 2FVY 0.92 7.8 309 
32 2GGC 1.00 7.0 263 
33 2H3L 1.00 7.5 103 
34 2IIM 1.00 7.5 62 
35 2IXT 0.80 7.5 310 
36 2P5K 1.00 6.5 64 




38 2PPN 0.92 7.0 107 
39 2PVB 0.91 8.0 108 
40 2QSK 1.00 8.0 95 
41 2QXI 1.00 6.5 224 
42 2VHK 0.94 7.1 206 
43 3EA6 0.92 7.0 219 
44 3FSA 0.98 7.0 125 
45 3GOE 0.97 7.7 82 
 
Table 2.11. Proteins in the loop set (11-13 residues). 
No. PDB ID Resolution (Å) pH Length (residues) 
1 1A8D 1.57 7.0 452 
2 1AKO 1.70 7.0 268 
3 1AOL 2.00 6.5 228 
4 1AOZ 1.90 5.4 552 
5 1ARB 1.20 7.4 268 
6 1BHE 1.90 6.5 376 
7 1BKP 1.70 6.5 278 
8 1BN8 1.80 6.5 420 
9 1BOL 2.00 6.7 222 
10 1BX4 1.50 7.5 345 
11 1C5E 1.10 6.5 95 
12 1CB0 1.70 7.4 283 
13 1CB8 1.90 6.5 678 
14 1CNV 1.65 8.0 299 
15 1CS6 1.80 7.5 382 
16 1D0C 1.65 6.5 444 
17 1DPG 2.00 5.6 485 
18 1DQZ 1.50 7.8 280 
19 1DYS 1.60 7.5 348 
20 1ED8 1.75 7.5 449 
21 1EDT 1.90 7.0 271 
22 1EL5 1.80 7.0 389 
23 1EOK 1.80 7.0 290 
24 1EUR 1.82 7.0 365 
25 1EXM 1.70 7.0 406 
26 1F46 1.50 7.5 140 
27 1FGK 2.00 6.5 310 
28 1G6S 1.50 7.0 427 




30 1G9G 1.90 7.5 629 
31 1GMU 1.50 6.5 143 
32 1GPI 1.32 7.0 431 
33 1GQV 0.98 6.5 135 
34 1H4A 1.15 7.0 173 
35 1HXH 1.22 7.5 253 
36 1I4J 1.80 7.0 110 
37 1I7P 2.00 7.5 274 
38 1IIR 1.80 6.5 415 
39 1IOO 1.55 6.5 196 
40 1IU8 1.60 7.4 206 
41 1IYE 1.82 7.5 309 
42 1JP4 1.69 6.5 308 
43 1KBL 1.94 7.0 873 
44 1KCM 2.00 6.5 270 
45 1KRH 1.50 7.0 338 
46 1L8A 1.85 7.1 886 
47 1LKI 2.00 7.0 180 
48 1LMI 1.50 7.0 131 
49 1M3S 1.95 6.5 186 
50 1MLA 1.50 7.0 309 
51 1MO9 1.65 6.5 523 
52 1MS9 1.58 7.5 648 
53 1MY7 1.49 7.5 114 
54 1NLN 1.60 6.5 204 
55 1NOG 1.55 7.5 177 
56 1NSC 1.70 7.0 390 
57 1O6L 1.60 7.5 347 
58 1OCK 1.80 7.0 412 
59 1OJQ 1.68 6.5 212 
60 1OTH 1.85 7.5 321 
61 1OYC 2.00 7.0 400 
62 1P1M 1.50 7.0 406 
63 1PGS 1.80 7.0 314 
64 1PKH 1.42 7.0 204 
65 1QLW 1.09 7.0 328 
66 1QQP 1.90 7.5 328 
67 1T1D 1.51 7.5 100 
68 1WHI 1.50 7.0 122 




70 2HLC 1.70 7.0 230 
71 2PTD 2.00 7.5 298 
72 2TGI 1.80 7.0 112 
 
Table 2.12. Proteins in the super long loop set (14-20 residues).  
No. PDB ID Resolution (Å) pH Length (residues) 
1 1AH7 1.50 7.0 245 
2 1BHE 1.90 6.5 376 
3 1C1K 1.45 6.5 217 
4 1DJ0 1.50 6.5 264 
5 1E6U 1.45 6.5 321 
6 1GPI 1.32 7.0 431 
7 1GQ6 1.75 7.5 313 
8 1H4A 1.15 7.0 173 
9 1J83 1.70 7.0 180 
10 1JP4 1.69 6.5 308 
11 1JU3 1.58 7.5 585 
12 1KWG 1.60 6.5 645 
13 1N0Q 1.26 7.0 93 
14 1NC5 1.60 7.5 373 
15 1O97 1.60 6.5 584 
16 1OCK 1.80 7.0 412 
17 1ODM 1.15 7.5 331 
18 1P3C 1.50 7.0 215 
19 1P3D 1.70 7.5 475 
20 1Q0R 1.45 7.5 298 
21 1QAZ 1.78 7.5 351 
22 1QL0 1.10 6.5 2.41 
23 1QLW 1.09 7.0 328 
24 1QQF 1.45 7.0 277 
25 1R6D 1.35 6.5 337 
26 1R6X 1.40 6.5 395 
27 1RA0 1.12 7.5 430 
28 1RDQ 1.20 8.0 370 
29 1RQW 1.05 6.8 207 
30 1RV9 1.53 7.0 259 
31 1RYO 1.20 7.7 327 
32 1S95 1.60 7.5 333 
33 1UG6 0.99 7.4 431 




35 1V8H 1.20 6.1 107 
36 1VJU 1.40 6.5 309 
37 1VYR 0.90 6.2 364 
38 1WB4 1.40 7.5 297 
39 1WHI 1.50 7.0 122 
40 1WM3 1.20 8.0 72 
41 1WRJ 2.00 7.5 156 
42 1WUI 1.04 7.4 156 
43 1XFK 1.80 7.3 336 
44 1XU1 1.90 7.5 138 
45 1Y12 1.95 7.5 165 
46 1YW5 1.60 7.5 177 
47 1ZEQ 1.50 7.5 84 
48 1ZHV 1.50 6.8 134 
49 1ZHX 1.50 6.5 438 
50 2AEB 1.29 7.1 322 
51 2B0T 1.75 7.3 738 
52 2BG1 1.9 7.0 494 
53 2BWR 1.5 6.5 401 
54 2C0H 1.6 6.5 353 
55 2CJP 1.95 7.5 328 
56 2DSJ 1.80 7.3 423 
57 2EX2 1.55 6.5 458 
58 2FAO 1.50 6.5 309 
59 2GGC 1.00 7.0 263 
60 2H2Z 1.60 6.0 306 
61 2H3L 1.00 7.5 103 
62 2HDW 2.00 6.5 367 
63 2HKJ 2.00 7.5 469 
64 2HLY 1.60 6.0 207 
65 2O2K 1.60 7.5 355 
66 2OIT 1.65 6.5 434 
67 2PEF 1.60 7.5 373 
68 2PKF 1.50 6.5 334 
69 2PUH 1.82 7.0 286 
70 2PVQ 1.80 7.0 201 
71 2PYW 1.90 6.5 420 
72 2QMM 1.85 7.5 197 
73 2V3V 1.99 6.5 723 




75 3A3P 1.90 6.5 329 
76 3B40 2.00 7.0 417 
77 3B64 1.03 7.5 112 
78 3BB7 1.50 6.5 321 
79 3BF7 1.10 7.0 255 
80 3BY9 1.70 7.5 260 
81 3CFZ 1.70 7.0 292 
82 3CNQ 1.71 6.5 292 
83 3CSS 1.70 7.5 267 
84 3CUZ 1.04 7.5 532 
85 3DRF 1.30 7.0 590 
86 3DSK 1.55 7.5 495 
87 3E7H 1.70 6.5 103 
88 3EA1 1.75 6.5 298 
89 3EH1 1.80 7.5 751 
90 3EHR 1.95 6.5 222 
91 3F1L 0.95 7.5 252 
92 3FOT 1.75 7.5 519 
93 3GGQ 2.00 7.5 149 
94 3H2G 1.86 6.7 397 
95 3HUH 1.50 7.5 152 
96 3HXL 1.90 7.5 446 
97 3IFE 1.55 6.5 434 
 
 







VSGB 2.0  VSGB 1.0 














1E6U A274 14 0 0.27 0.85  -7 1.94 2.93 
1JP4
a,b
 A153 14 -4 0.31 0.67  -43 7.26 6.32 
1N0Q A24 14 -12 0.51 1.55  -4 0.22 1.76 
1N0Q A57 14 -10 0.50 2.29  -13 0.52 2.34 
1O97 D156 14 -8 0.68 1.93  -13 0.82 1.55 
1OCK A209 14 -18 1.13 1.80  -22 0.92 1.86 
1P3C A112 14 -18 0.31 1.28  -7 0.32 0.94 
1P3D A402 14 0 0.35 0.40  6 1.74 4.99 
1R6X A72 14 2 0.25 0.41  1 0.30 0.48 




1RV9 A225 14 3 0.28 1.92  9 0.26 2.20 
1VYR A193 14 -6 0.51 1.76  4 0.58 1.57 
1VYR A235 14 -7 0.93 1.98  6 1.17 3.06 
1XU1 A221 14 -4 0.69 2.12  4 0.47 1.58 
1ZEQ X53 14 -18 0.21 2.10  -15 0.27 2.01 
2BWR A269 14 -22 0.31 1.70  -3 0.44 2.35 
2BWR B158 14 -2 0.41 1.85  35 4.56 7.40 
2C0H
b
 A40 14 0 0.55 1.56  108 5.96 8.85 
2EX2 A139 14 -18 0.32 1.50  -8 0.21 1.47 
2GGC A79 14 -8 0.28 1.70  -8 0.24 1.95 
2H3L A1360 14 -12 0.36 2.10  1 0.28 1.84 
2O2K A1221 14 -1 0.29 1.47  -29 1.07 2.36 
2PVQ A139 14 -13 0.57 1.31  6 0.66 1.62 
2VFR A325 14 -3 0.19 0.33  -14 0.34 1.43 
3B40 A389 14 1 0.33 0.89  48 1.28 2.07 
3B64 A44 14 -1 0.24 1.04  -25 0.65 2.09 
3BY9 A177 14 2 0.47 1.66  -24 1.13 2.70 
3BY9 A205 14 -6 0.32 0.81  -11 0.28 0.81 
3CFZ A125 14 -8 0.54 1.99  1 0.68 1.92 
3CNQ S50 14 -2 0.63 1.88  -9 1.03 2.28 
3CSS A163 14 0 0.19 0.27  0 0.21 0.27 
3DRF
b
 A550 14 -10 1.04 2.51  1 1.85 3.38 
3E7H A67 14 -3 1.27 3.41  -6 1.78 2.85 
3EHR A95 14 -4 0.51 3.40  7 0.94 1.78 
3FOT A164 14 -14 0.34 1.41  -14 0.30 1.40 
3HXL A277 14 0 0.77 3.74  28 0.79 3.92 
1AH7 A157 15 -13 0.55 1.75  -1 0.32 1.11 
1BHE A121 15 -3 0.76 2.52  -1 0.42 1.88 
1H4A X19 15 -1 0.31 1.22  -4 0.28 1.26 
1JU3 A486 15 0 1.09 2.51  5 0.35 1.64 
1QAZ A298 15 -29 0.99 3.00  -7 1.68 3.72 
1QQF A1112 15 -2 0.53 0.69  -8 0.31 2.03 
1RA0 A283 15 7 0.30 2.16  -39 2.78 5.46 
1RA0 A361 15 -5 0.52 1.66  -4 0.39 2.15 
1RYO A172 15 -1 1.17 1.60  -5 0.88 1.64 
1S95 A477 15 -15 0.46 1.86  -5 0.61 2.09 
1WB4 A1033 15 -1 0.15 0.47  1 0.21 0.80 
1WUI L454 15 2 0.97 2.96  -12 1.81 3.76 
1Y12 A10 15 -2 0.62 2.81  -2 0.36 2.10 




2AEB B156 15 5 1.32 2.69  25 2.55 5.23 
2B0T A701 15 1 0.94 1.63  3 1.23 3.74 
2CJP A58 15 -9 0.43 0.77  12 0.46 0.98 
2DSJ A354 15 -7 0.57 1.89  -5 0.51 1.85 
2H3L A1339 15 -10 0.35 2.02  -10 1.10 1.88 
2O2K A1220 15 13 1.53 3.28  -29 1.36 3.38 
2OIT A290 15 7 0.80 2.32  6 0.54 2.30 
2PKF A26 15 0 0.65 1.59  -8 2.34 5.06 
2V3V A382 15 -6 0.41 1.78  4 0.35 1.94 
3A3P A286 15 4 0.22 1.71  5 0.18 0.99 
3A64 A350 15 -7 0.20 1.22  3 2.55 3.34 
3BB7 A231 15 -9 0.33 2.06  -19 6.26 7.60 
3BF7
b
 A49 15 3 0.58 1.58  72 5.66 9.28 
3CSS A95 15 -17 0.52 1.39  -24 2.36 3.79 
3EA1 A136 15 17 0.76 1.79  7 0.49 1.08 
3F1L A99 15 -5 0.50 1.44  -16 1.05 1.76 
1C1K A31 16 -8 1.71 2.67  12 0.66 1.67 
1DJ0 B19 16 6 1.66 4.24  72 7.08 13.52 
1GPI A308 16 -11 0.52 1.04  -5 0.33 0.68 
1UG6 A340 16 4 0.37 1.08  4 0.43 1.03 
1WHI A88 16 -13 0.47 2.34  -17 0.66 1.79 
1WM3 A67 16 -10 0.23 1.24  13 0.32 0.52 
1ZHV A20 16 -6 0.30 1.03  -10 0.64 1.05 
2BG1 A708 16 -3 0.40 0.92  -4 2.15 2.76 
2GGC A184 16 -12 1.17 2.33  -89 1.08 3.84 
2HKJ A418 16 -16 0.36 1.11  -42 0.42 1.59 
2PKF B25 16 -42 0.95 2.89  -93 0.93 3.38 
2PUH A70 16 -5 0.30 0.96  -14 1.52 3.25 
2PYW A321 16 -1 0.99 3.45  -37 2.57 6.1 
3IFE
b
 A14 16 -13 0.32 0.57  -55 1.18 3.68 
1KWG A314 17 0 0.57 1.73  -41 1.93 2.92 
1QLW A145 17 -8 0.35 2.11  0 0.41 1.29 
1VJU A277 17 4 0.38 1.82  -2 0.63 1.55 
2FAO A814 17 3 0.86 1.84  21 0.50 1.27 
2HDW A131 17 10 0.60 1.63  -126 2.22 5.96 
2PEF A191 17 2 1.32 2.97  44 1.92 3.55 
3A3P A262 17 16 0.21 0.96  -250 0.52 2.79 
3H2G
b
 A124 17 -24 1.00 1.50  56 4.07 6.75 
3HUH
b
 A71 17 -6 0.29 1.98  -39 8.56 12.13 




1NC5 A121 18 16 0.26 0.91  129 9.78 13.27 
1J83 A1073 18 11 0.27 0.96  47 4.86 5.46 
1R6D A132 18 13 0.35 1.54  11 0.67 1.28 
1RQW A69 18 6 1.29 3.93  1 0.43 3.24 
1UW4 B899 18 5 1.97 1.79  -102 11.27 11.47 
1WRJ A53 18 -10 0.49 1.27  -30 1.55 2.79 
1XFK A258 18 -7 0.56 1.33  8 1.42 1.92 
2AEB A153 18 -5 1.15 2.71  - - - 
2H2Z
b
 A130 18 -3 1.49 2.86  -3 1.48 2.07 
2QMM
b
 B103 18 5 0.79 2.15  34 8.95 9.18 
3CUZ A384 18 4 0.82 2.00  -22 3.45 5.94 
3DSK A425 18 12 0.39 1.03  26 5.78 7.50 
3EA1 A164 18 10 0.65 1.45  108 3.70 4.23 
3EH1
b
 A813 18 11 1.60 2.37  -22 2.84 4.58 
3GGQ A550 18 8 0.37 1.54  -26 5.12 7.46 
1NC5 A193 19 -12 1.79 3.81  1.06 3.66 4.96 
1ODM
b
 A119 19 16 1.94 3.39  5.59 1.31 2.50 
1Q0R 
b
 A58 19 7 1.51 5.07  -3.99 3.87 5.37 
1QL0 A150 19 -6 1.02 1.72  -7.68 1.29 2.36 
1V8H
b
 A27 19 11 1.74 5.42  15.95 7.59 8.64 
2HLY A126 19 10 1.60 3.13  -1.08 0.48 1.54 
2O2K A947 19 3 0.25 1.70  0.73 0.33 1.72 
1QL0 A47 20 -2 1.29 2.45  -0.73 0.67 1.93 
1YW5
b
 A76 20 4 1.80 3.18  -4.51 2.51 3.45 
2AEB
b
 A50 20 -16 1.68 3.02  -9.02 1.12 2.75 
a. Explicit treatment with key water molecules between crystal copies. 
b. Extended sampling to “Fix10” stage. 
 
 
Figure 2.11. Comparison of the linear function and the polynomial of hydrophobic term (for one 




Chapter 3. Predictions of P450-mediated Drug Metabolism 
3.1. Introduction 
It is crucial to understand how potential drugs are metabolized in the body, because 
human metabolism has profound impacts on the bioactivity and the safety profiles of drug 
candidates. On one hand, metabolism can convert these compounds into their active forms, 
which interact with the therapeutic targets; on the other hand, metabolism eliminates the 
compounds by converting them into inactive excretable metabolites. Sometimes the metabolic 
modifications also lead to toxicity, which can cause unexpected failures in the later phases of 
drug development. Furthermore, the metabolic behavior of drug compounds is also highly related 
to other critical issues such as food-drug interactions, drug-drug interactions, and personalized 
medication.
103-105
 Given the enormous impact of metabolism on drug bioavailability and toxicity, 
it is important to determine metabolites in the early stage of the drug discovery process. However, 
to obtain such information experimentally is often a very lengthy and expensive process. 
Therefore, it would be extremely useful if one could use computational methods to predict the 
metabolic decomposition of drug candidates. 
Since cytochrome P450 enzymes (CYP) are involved in a large majority of drug 
metabolism pathways, many computational studies have been published attempting to predict 
P450-mediated metabolism using a variety of methods and models. For a recent review see the 
work of Afzelius et al.
106
 These previous studies mainly focused on the important P450 isoforms 
2D6, 2C9 and 3A4 aiming to predict the primary metabolites of drug compounds. Several ligand-
based methods have been developed during the past decade, making predictions based on 
hydrogen abstraction energies estimated with semiempirical quantum mechanics
107
 or DFT 
methods
108




the interaction between the enzyme and the substrate in order to reach high accuracy (for 
example, >80% agreement with experiments) in the predictions. It is possible to include a limited 
amount of enzyme specific information by making descriptors of ligand-based models dependent 
on the nature of the enzyme.
41,109,110
 Such approaches have been successfully implemented in 
software packages such as MetaSite and some were reported to recover up to 86% of the 
experimental observations.
111
 On the other hand, molecular dynamics (MD) or induced-fit 
docking simulations in combination with transition state calculations at the QM/MM or 
semiempirical quantum level were used to predict metabolites for a few ligands.
112,113
 Other 
promising methods based on molecular docking have been implemented as well,
114-118
 which 
determine the predictions using a reactivity model and/or distance cutoffs from the reactive iron 
center.  
Traditional empirical ligand-based approaches to the prediction of P450 SOMs rely 
primarily on implicit estimation of intrinsic site reactivity to the Compound I oxo species, 
coupled with a heuristic attempt to take into account the ability of the ligand to bind to the P450 
active site. While such methods can yield some discrimination of true positives from false 
positives when a sufficiently large training set is employed,
41,107,119
 the precision of the approach 
is fundamentally limited, as the treatment of protein-ligand binding is highly approximate. 
Methods such as MetaSite
111
 provide some incorporation of  P450 structural information, but 
employ a much smaller training set and fewer empirical parameters; the overall results appear to 
actually be less accurate than a ligand-based approach employing an extensive data set. The 
problem is again that the MetaSite algorithm for modeling the reactive protein-ligand complex 
does not rigorously evaluate the binding energy, or perform a thorough conformational search, 




The method described in the present work (IDSite) represents a qualitatively different 
approach from those discussed above, as well as from other efforts in the literature.
41,108,110,111
 
Firstly, the goal is to actually generate an accurate structure for the protein-ligand complex that 
enables reactivity at a specified site; this requires construction of a good approximation to a 
transition state structure for both aliphatic and aromatic sites of reaction. Secondly, the relative 
binding affinity, as compared to alternative structures for both the site in question and for other 
sites, has to be computed with a respectable degree of precision, on the order of a few kcal/mol. 
Finally, The relative intrinsic barrier height of the reaction (combined with the relative binding 
affinity to produce an overall relative barrier , as compared to other possible reactions of the 
molecule, must be estimated, to within ~1 kcal/mol. These are extraordinarily daunting tasks, 
given that the P450 isoforms present large, complex active site regions with substantial 
capability for induced-fit conformational changes, a necessary condition for them to 
accommodate the wide range of exogenous ligands with which they need to interact to perform 
their biological function. 
The algorithms in IDSite employ a novel model for the total energy of the protein-ligand 
complex, which has recently been show to provide remarkably accurate predictions for side 
chains and loops
120
, and a sophisticated algorithm for generating converged induced-fit structures 
which combines docking, conformational search, and hybrid Monte Carlo (MC) methods based 
on MD trajectories. The algorithm enables a hierarchical search which addresses the various 
length scales of the problem, including the small correlated motions provided by the MD 
trajectories which we have found are absolutely necessary to produce useful rank ordering of 
structures, particularly for larger ligands. Constraints are employed in conjunction with these 




enables the targets of a few kcal/mol accurate in relative binding affinity to be reached. Finally, a 
quantum chemically based model is employed to calculate relative intrinsic reactivities, and 
again is shown below to yield outstanding performance. Based on such high level of success, it is 
documented below in predicting true positive SOMs vs. false positives. 
To our knowledge, these results represent the first reliable and accurate computation of 
binding poses and transition states for a wide range of drug-like molecules interacting with an 
important human P450 isoform. There are a few previous papers in which structures are 
generated via QM/MM calculations,
113,121,122
 however these typically address a very small 
number of ligands (usually one), the ligands are typically simpler and smaller than those treated 
here, and the sampling algorithms are much less extensive. We believe that these structures can 
be very useful in practical drug design applications, in situations where modification of P450 
metabolic properties for candidates in later stages of lead optimization is required. The 
availability of an atomic level three dimensional structure, as well as the ability to predict the 
structural and energetic effects of chemical modification of the molecule, provides a new tool for 
chemists to rationally engineer desirable metabolic properties into clinical candidates. Extension 
of our methods to other P450 isoforms such as 2C9, 3A4 and 1A2, which is currently in progress, 
will enhance the utility of our approach for this important application. 
 
3.2. Methods and Materials 
Overview of IDSite Methodology 
IDSite combines the docking program Glide
123
 and the protein structure modeling 
program PLOP (Protein Local Optimization Program, available as the protein refinement module 
in the protein modeling package Prime of Schrödinger, Inc.
124
), to model induced fit effects and 




scoring stage (Figure 3.1). It begins with flexible Glide docking calculations, which place the 
ligand into the active site. Following the docking stage, two refinement stages in PLOP are 
carried out to refine the protein side-chain and ligand orientations. At the end of each sampling 
stage, the generated/refined poses are screened based on their structures and energies, and 
clustered according to the similarity of the ligand conformation. Finally, the refined lowest 
energy poses are used to predict the sites of metabolism based on a physical score, which is 
dependent on the energies of the poses as well as the intrinsic chemical reactivities of the 
potential sites of metabolism.  
IDSite is able to use knowledge about specific conserved interactions to perform efficient 
sampling and accelerate the calculations. For example in the case of CYP2D6, a typical substrate 
always contains a basic center (e.g. an amine nitrogen) that binds to one of the two acidic 
residues, Glu216 or Asp301. IDSite constrains such salt bridges to reduce the sampling cost 
associated with the docking and refinement stages. Filters are applied during the screening at the 
end of each stage in IDSite to reduce the number of poses passed to further refinement or 
evaluation (Table 3.1). The following is a detailed description of each stage of IDSite.  
We have constructed our sampling and scoring algorithms with the intention of 
approximating the correct transition state structure of the protein-ligand complex and associated 
activation energy which would lead to reactivity of the target atom of the ligand. There are two 
components of the problem: finding the transition state in reasonable CPU time (a daunting task 
for a large, complex ligand when induced fit effects are important), and estimating the free 
energy of activation associated with the transition state. The VSGB 2.0 energy function, with 
constraints to enforce a suitable geometry for the reaction to take place (and some other 




generate these structures for the various possible candidate reactant heavy atoms. We use the 
classical force field and solvation model to produce a “reactant” structure which is optimally 
positioned for the targeted chemical reactivity. The activation barrier from a precomputed 
quantum chemical fragment calculation, as described in the following text, is then added to the 
VSGB 2.0 energy to estimate the relative energy barrier for converting such a structure into 
products. This is an approximation to a more rigorous approach such as using QM/MM methods 
to generate the reactant, transition state, and product structures. Note that it is only important that 
relative free energy of the various potential sites of reaction are calculated with reasonable 
accuracy, as the most reactive (lowest activation free energy) site is always used as a reference 
point (i.e. the energy function for this site is subtracted from the energy function for the 
candidate site) in our assessment of the metabolic contribution of each site. Finally, in applying 
the above protocol, the VSGB 2.0 energy must be calculated using a structure with the 
constraints in place, otherwise the structure would minimize to something that is not a suitable 
starting point for reaction. The constraints introduce some strain energy into the structure, but 
this strain energy is an appropriate component of the activation free energy as it does cost energy 










Table 3.1. IDSite filters in the screening for CYP2D6. 
Stage Filters applied in the screening at the end of the stage 
Glide Docking 
Poses that fulfill any of the criteria below are removed: 
1) The distance of the basic nitrogen to the ferryl oxygen is 
less than 5.0 Å; 
2) The distance of the basic nitrogen to the negative charged 
oxygen (in Glu216 or Asp301) is greater than 5.5 Å; 
3) More than 2 heavy atoms from the ligands are further than 
16.0 Å away from the heme iron; 
4) More than 1 heavy atom from the ligand are closer than 
1.0 Å to the receptor; 
5) More than 6 heavy atoms from the ligand are closer than 
1.8 Å to the receptor; 
6) No heavy atom in the ligand is within 5.0 Å to the heme 
iron. 
 
For PLOP Refinement 1: 
All the poses are ranked with PLOP energies. Poses with energy 
higher than 35 kcal/mol compared to the lowest energy pose are 
removed. 
PLOP Refinement 1 
PLOP Refinement 2 
Poses that fulfill any of the criteria below are removed: 
1) the distance between the constrained atom and the ferryl 
oxygen is outside the optimal range which is from 1.65 to 
2.60 Å for sp
3




2) the distance of the basic nitrogen to the ferryl oxygen is 
less than 4.8 Å; 
3) the distance of any polar atom to the ferryl oxygen is less 
than 3.2 Å; 
4) the distance of the  constrained salt bridge (between the 
basic nitrogen and the oxygen from Glu216 or Asp301) is 
greater than 3.6 Å; the angle of the salt bridge (N-H-O) is 
less than 140 degree; 
5) more than 2 heavy atoms from the ligands are either 
further than 14.5 Å or closer than 1.6 Å from the heme 
iron; 






Starting from the ligand and the protein receptor structures, IDSite carries out flexible 
ligand docking with Glide.
18,19
  The flexible ligand docking protocol generates a large number of 
ligand conformations that are then docked into the rigid receptor. The first step in Glide docking 
is to define the binding box and calculate the receptor grid. As in Glide, in IDSite the binding site 
is defined as a box centered at the center of selected residues or a ligand (if the structure contains 
a ligand).  Because we start from the apo structure of CYP2D6 (PDBID: 2F9Q. See below for 
details about the protein preparation), the center of the binding box is selected as the centroid of 
the residues Glu216, Asp301, Thr309, and Phe483. The box dimension on each side is set to 10 
Å for the inner box and 20 Å for the outer box. After the grid generation, IDSite samples the 
conformations of freely rotatable bonds and rings with Glide Standard Precision (SP). In order to 
increase sampling, IDSite uses reduced Van der Waals (VDW) radii and skips the default 
filtering with a rough score within Glide (also referred to as expanded sampling). Similar poses 
are clustered according to their RMSD (cutoff 2.0 Å). Finally, a post-docking minimization is 
performed and the top 60 minimized poses according to the Glide SP score are retained. These 
poses are then screened to remove the poses with obvious steric clashes, with too many atoms 
outside the inner binding box, or without atoms close to the heme iron (Table 3.1). The 
remaining poses are then passed to the first refinement stage. 
IDSite uses reduced VDW radii for nonpolar atoms both in the protein receptor and the 
ligand, so that slight steric clashes are tolerated during the docking stage. For the protein receptor 
the VDW scaling factor is fixed at 0.40, while for the ligand, the scaling factor starting from 0.80 
is adaptively adjusted until at least 4 valid poses are found. With highly flexible ligands and 
relatively high scaling factors, Glide often finds only a handful of valid poses, and even fewer 




may contain too many serious steric clashes, which can cause problems in the subsequent 
minimization. If IDSite fails to find enough valid poses, the scaling factor is adjusted and the 
number of poses to pass the initial docking phase in Glide is increased accordingly to augment 
sampling.  
Since a typical CYP2D6 substrate forms a highly conserved salt bridge with either 
Glu216 or Asp301,
125
 IDSite employs this conserved interaction to reduce the sampling cost of 
the CYP2D6-docking in the following way: IDSite adds a positional constraint to ensure that the 
generated poses fulfill at least part of the preferred conserved interactions. The positional 
constraint defines a spherical region in the receptor that is within 4.0 Å of the center of the 
Glu216, Asp301, and Ser304 residues (Figure 3.2). It is required that during docking and post-
docking minimization each pose should maintain at least one hydrogen-bond donor inside the 
spherical region. If the ligand contains other hydrogen-bond donors except for the basic nitrogen, 
the constrained docking is likely to generate poses that form hydrogen bonds instead of the salt 
bridge to Glu216 or Asp301. However, IDSite is able to distinguish these poses and filter them 
via an additional salt bridge filter in the pose screening (Table 3.1), so that only the poses with a 





Figure 3.2. Definition of the binding box (yellow cube) and the positional constraint (yellow 
dotted sphere) in IDSite for CYP2D6. 
 
PLOP Refinements 
The refinement of the docked poses includes multiple, parallel Monte Carlo Minimization 
(MCM) simulations in PLOP. For each pose from the previous stage (the docking or first 
refinement stage), IDSite finds all the heavy atoms in the ligand close to the heme iron. For each 
of these atoms, distance and angular harmonic constraints are applied in order to force sampling 
of the conformations that potentially lead to metabolism. The optimal distances and angles of the 
constraints were obtained from hydroxylation transition state geometries with a heme model 
system at the B3LYP/LACVP* level using Jaguar.
126
 The detailed nature of the employed 




 type carbons in Figure 3.3 and 3.4. The constraints are 
then employed in the minimizations step but were not included in the energy used for the 
acceptance step of the MCM simulations. PLOP uses the overlap factor (the ratio of distance 
between two atoms centers to the sum of their atomic radii) to quickly reject randomized 




cutoff). PLOP repeats the random attempts until a structure with tolerable clashes is generated, 
after which a constrained minimization using the truncated Newton method is performed. The 
acceptance or rejection of the minimized structure is decided by the Metropolis criteria based on 
the energy calculated in the VSGB 2.0 model. (Performing the minimization step before testing 
the acceptance criteria violates detail balance, but this is not an issue as we are interested only in 
low energy structures and not the population/ensemble distribution.) The simulations run until a 
certain number of accepted structures are collected. 
In order to sample the various degrees of freedom in the conformational space, IDSite 
employs three types of randomized moves in the MCM simulations: side-chain rotation, rigid 
body translation/rotation, and hybrid moves. 
 
Side-chain moves: By varying the dihedral angles of the rotatable bonds, IDSite uses side chain 
MC moves in PLOP to sample the selected side-chain conformations of the protein and of the 
ligand. Up to three close residues (Cβ distance within 6 Å) are allowed to rotate collectively, but 
the moves of the protein residues and those of the ligand are separated. In each attempted 
movement, the conformations of the selected side chains (from the protein/ligand) are either 
changed by random perturbations or assigned by the randomly selected rotamers from a library. 
For an attempt with a random perturbation, the displacement of each dihedral angle is the sum of 
a large rotation (N times 60 degrees with N as a random integer between 0 and 5) and a random 
perturbation from 0 to 30 degrees. For a rotamer library attempt, a side-chain conformation is 
updated with a random rotamer from a high resolution side-chain library for protein residues
79
, 
and from a homogeneous library at 10 degree resolution for the ligand. If a structure with 




judgment of acceptance. Each side-chain move takes less than 15 seconds and is the fastest 
among all the three move types. 
 
Rigid body moves: Rigid body moves are used to sample the translational and rotational space 
of the ligand. Multiple attempts with reduced VDW radii are applied, as it is quite common to 
fail in searching for a clash-free conformation in a single rigid body moving attempt (especially 
when the ligand is large and flexible and the binding pocket is relatively small). Each rigid body 
move includes 1000 attempts, and each attempt performs a translation along a random vector and 
a rotation around a random axis, with less than 0.5 Å and 60 degree displacement, respectively. 
In addition, the VDW radii are reduced (scaling factor 0.8) to soften the Lennard-Jones potential, 
so that mild steric clashes are allowed, which are likely to be resolved by the subsequent 
minimization. The rigid body move usually takes 20 to 40 seconds per move.  
 
Hybrid Monte Carlo moves: The hybrid Monte Carlo (HMC)
127
 move in PLOP performs 
simultaneous sampling for the selected residues in the protein side chains and backbone as well 
as the ligand. Each HMC move performs a 5 picosecond, constant energy molecular dynamic 
(MD) simulation (starting at 900K) on all the atoms in the selected residues. Taking up to 15 
minutes per move, the HMC is the most expensive among all three types of moves in PLOP.  
Considering the different costs for the three types of moves, the frequency of deployment 
of each move type in the various refinement stages is adjustable according to the sampling 
requirements. Two stages of refinement with different combinations of moves and constraints are 
carried out in the hierarchical sampling. Using more HMC moves, the first refinement stage 




oxygen. It is designed to “pull” the close atom (identified from the docking poses) towards the 
heme iron, to estimate the likelihood that the atom can approach the iron and react with the ferryl 
oxygen. When an atom in the ligand is forced to be proximate to the ferryl oxygen under the 
constraints, the rest of the ligand and the surrounding protein residues have to adjust their 
conformations accordingly. The adjustments for some poses are easy while for some others are 
difficult, depending upon the specific geometrical issues and energetics of the protein-ligand 
interactions for the trajectory connecting particular starting and target poses. Resulting poses 
with steric clashes or distorted structures can be identified by their high energies and discarded in 
the IDSite energy and structure screening (Table 3.1). The low energy poses after screening, 
mostly with favorable interactions between the protein and the ligand, are passed to the second 
refinement stage. Mainly focusing on side-chain sampling, the second refinement stage applies 
tight constraints that force the structure to form special conformations similar to that of the 
transition states obtained from DFT calculations of model systems. The second refinement stage 
is used to further refine the poses and distinguish the potential of each atom in question to be 
oxidized. The comparison of the settings for these two refinement stages with PLOP are shown 
in Table 3.2, while the constraints are illustrated in Figures 3.3 and 3.4. There are approximately 
39 protein residues, identified to be important for ligand binding by mutagenesis experiments or 
are adjacent to these key residues that are sampled during the refinement stages. At the end of 
each refinement stage, all the poses sampled in that stage are screened and clustered for further 
refinement or evaluation (Table 3.1). 
For CYP2D6, harmonic constraints are also applied to force the basic nitrogen to interact 
with the acidic residues, Glu216 and Asp301 (Figure 3.5 and 3.6), as they are believed to play 








Figure 3.3. Constraints applied to the heme region in the first refinement stage. The ferryl 
oxygen is a “dummy” atom (1.6 Å above the heme iron), only used to define the constraints in 
the IDSite calculations. (A) Constraints for sp
3









Figure 3.4. Constraints applied to the heme region in the second refinement stage. The ferryl 
oxygen is a “dummy” atom (1.6 Å above the heme iron), only used to define the constraints in 
the IDSite calculations. (A) Constraints for sp
3
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Table 3.2. Comparison of settings in the first and second refinement stages. 
 PLOP Refinement 1 PLOP Refinement 2 
Number of residues to sample 
(including the ligand) 
12 40 
Number of accepted 
structures for each job 
Maximum of 8 times the 
number of rotatable bonds, 24 
Maximum of 20 times the 
number of rotatable bonds, 60 
Types and probabilities of 
MCM moves 
Side chain: 0.50 
Rigid body: 0.10 
Hybrid: 0.40 
Side chain: 0.70 
























Herein, we present two scoring models to evaluate the potential sites of metabolism and to 
determine the predictions. Our first scoring model (referred to as Physical IDSite) is based on the 
following assumptions: (1) For hydroxylation of an aliphatic chain carbon, the P450-hydrogen abstraction 
step is rate determining.
130,131
 (2) For hydroxylation of aromatic rings, the electrophilic attack of 
Compound I on the aromatic ring is rate determining.
130,131
(3) All reaction intermediates before the rate 
determining step are in equilibrium.
132
 Given these assumptions, the relative rates of product formation 
depend only on the relative transition state free energies of the rate determining (RD) transition states 
(ΔG≠) according to the Curtin-Hammett principle. These can then simply be written as 
ΔG≠ = ΔGbind + ΔG
≠
RD-step                                                (Eq. 3.1) 
where ΔGbind is the binding free energy of the substrate into the reactive conformation in the P450 active 
site and ΔG≠RD-step is the activation barrier of the RD-step. 
 In the present application of IDSite, we attempt to calculate only relative, as opposed to absolute, 
site reactivity for a given ligand. Absolute site reactivity for the ligand can typically be obtained via 
inexpensive experiments. However, detailed metabolic chemistry is often more difficult to determine, and 
an accurate three dimensional structure leading to reactions at each metabolic site is not available given 
the severe challenge of obtaining a crystal structure of a P450 isozyme with the ligand bound in the 
reactive conformation. Prediction of the most highly reactive site, followed by identification of all sites 
with relative reactivities sufficiently large to be experimentally detected along the dominant metabolic 
pathway, coupled to structural prediction for each relevant reactive geometry, complements current 
experimental practice and facilitates compound modification in situations where P450 metabolism needs 
to be altered to confer improved metabolic properties on a candidate drug molecule.  
In the Physical IDSite model, the relative binding energies of various docked poses are calculated 




the corresponding activation barriers of model compounds with a methoxy radical (calculated at the DFT 
level). Epose in Eq. 3.3, calculated in PLOP, estimates the protein-ligand interactions when a potential site 
is forced to approach the catalytic center in a certain pose with a transition state-like conformation. Based 
on the linear correlation (Figure 3.7) between the methoxy radical activation barriers and the 
corresponding activation barriers with the heme system, we approximated the real activation barrier for 
each potential site of metabolism from the intrinsic reactivity calculated with the methoxy radical model 
according to Eq. 3.2. 
IR(heme) = 1.117 × IR(methoxy radical) + constant                            (Eq. 3.2) 
With the constant from Eq. 3.2 ignored, the relative ΔG≠ for each potential site (approximated as the score 
E) is then calculated as the Boltzmann weighted average over the energies of all contributing poses, 
where angle brackets represent the Boltzmann averages (Eq. 3.3). A term describing the configurational 
entropy of equivalent hydrogen atoms at 298 K, proportional to the logarithm of the number of 
symmetrically equivalent hydrogen atoms, was also included. The ΔG≠ values for all symmetrically 
equivalent sites were set to the lowest ΔG≠ of the sites. 
E= <1.117 × IR(methoxy radical) + Epose> - kTlnNH                       (Eq. 3.3) 
Since (as a rule of thumb) it is difficult to observe a minor metabolite experimentally if it is formed in less 
than ca. 0.1% yield (which corresponds to ca. 4.75 kcal/mol increase in relative ΔG≠ compared to the free 
energy of the most favored product), we used 4.75 kcal/mol as a cutoff for the prediction; with Physical 
IDSite, any potential sites of metabolism having a relative ΔG≠ lower than 4.75 kcal/mol is predicted to 
be a site of metabolism.  
The second scoring model represents an empirically optimized version of the physical model 
described above with the following changes: (1) The PLOP energy (Epose) is not used directly, but 
rescaled with two parameters as described below, which are fitted to a training set of 36 compounds. (2) 




correlation in Eq. 3.7, we fit it to the training set of 36 compounds. Note that the fitted value for the latter 
of 1.071 (Eq. 3.4) is very similar to the value obtained by correlating the DFT-activation energies (1.117), 
which further highlights the physical nature of this parameter. (3) The final selection criteria for 
predictions (score cutoff) were fit to the training set as well. All four fitted parameters were obtained from 
a fitting algorithm by maximizing the number of true positives over the sum of the numbers of false 
positives and false negatives. 
E = <1.071 × IR(methoxy radical) + Escore> - kTlnNH                    (Eq. 3.4) 
As introduced above, instead of directly using the PLOP energy (Epose), Eq. 3.4 recalculates the binding 
contribution (Escore) with a linear energy score; the angle brackets again represent Boltzmann averages. If 
a pose has a PLOP energy (Epose) within 5.26 kcal/mol from the lowest one, the energy score (Escore) is 
zero; otherwise, it is 0.58 times the relative energy. The potential sites that have relative score within 1.46 
kcal/mol of a site predicted to have the highest reactivity are considered to be a site of metabolism. 
 
Reactivity model: The sites at which a ligand gets metabolized by a P450 enzyme depends not only on 
whether the atom in question can approach the heme iron center with the correct geometry, but also on the 
intrinsic chemical reactivity of the site. Assuming that the intrinsic chemical reactivities of the ligand sites 
are independent of the presence of the enzyme, we estimated the intrinsic reactivities from activation 
energies of a library of model systems using QM. Since DFT with the B3LYP functional and the 6-31G* 
basis set has been shown to give high accuracy for relative energies of transitions states,
133
 while still 
allowing for fast calculations, we employed that level of theory for our intrinsic reactivity model. It has 
been shown that in general, an accurate linear correlation exists between the QM activation energies of 
hydrogen abstraction reactions with a methoxy radical and the corresponding hydrogen abstraction 
barriers with an iron-oxo porphyrin species, generally referred to as Compound I in the P450 
literatures.
130
 In agreement with previous reports,
134,135




correlation including aliphatic hydrogen abstraction barriers as well as aromatic ones. As shown in Figure 





 hybridized systems (R
2
=0.94), which validates the use of the methoxy radical model 
to estimate the intrinsic reactivities. Therefore, transition states for methoxy radical based hydrogen 
abstraction reactions were optimized at the B3LYP/LACVP* level of theory with Jaguar
126
 for a 
fragment library consisting of 150 model compounds, 483 distinct hydrogen atoms, and more than 2000 
conformations, in order to accurately model all distinct chemical environments. Carbon atom based 
intrinsic reactivities were then assigned as the Boltzmann weighted activation energies over different 
transition state conformations. Intrinsic reactivities of the ligand sites were assigned using a simple 
SMARTS string matching algorithm of the fragment library. Thereby the best matching fragment was 
determined as the one with (1) the largest number of heavy atoms (2) the most hydrogen atoms and (3) 
the largest sum of atomic numbers.  
 
Figure 3.7. Correlation between the intrinsic reactivities calculated with the methoxy radical 
model and the heme model (17 sites from selected 9 fragment compounds, details are shown in 




Preparation of Protein and Ligands 
The X-ray crystallographic structure of CYP2D6 was obtained from the Protein Data 
Bank (PDBID: 2F9Q, 3.0 Å resolution
136
) and contains a well-defined active site above the heme 
group. We applied the Protein Preparation Wizard (PPW) of Schrödinger Inc. to add hydrogen 
atoms, optimize the hydroxyl orientation, correct the Gln/Asn/His side-chain orientations, and 
determine the protonation states of titratable residues. PPW also assigned the bond order of the 
heme group and the iron oxidation state, which defines the iron atom as Fe
3+
 covalently bonded 
to the side chain of Cys443. The positions of all hydrogen atoms were optimized with a 
constraint of 0.3 Å with the OPLS 2005 force field. 
A training set of 36 compounds and a test set of 20 compounds were collected from the 
experimental literature.
37,137
 These compounds mainly undergo O-dealkylation and 
hydroxylation by CYP2D6. The training and test sets contain 774 and 383 heavy atoms, 
respectively. Details about the data selection are explained in the Supporting Information. All 
stereoisomers used in the experiments were enumerated as were the protonation states at pH=7.0. 
All structures were minimized in vacuum using the OPLS 2005 force field, prior to the IDSite 
calculations.  
 
3.3. Results and Discussions 
Tables 3.3 and 3.4 present the summary of our predicted results with the training set and 
the test set.  The data shows that IDSite has high sensitivity and specificity with both IDSite 
scoring models in predicting the 2D6-mediated metabolism of the 56 compounds; using the 
Physical IDSite scoring, we achieve high sensitivity (0.83) and high specificity (0.98); using the 
Fitted IDSite scoring, we can achieve even higher sensitivity (0.94) and similarly high specificity 




specificity 0.99) and test set (sensitivity 1.0 and specificity 0.98) are very similar, indicating that 
for the fitted model, no overfitting to the training set can be detected. 
It is interesting to note that the principal effect of the parameter fitting is to reduce the 
number of false negatives; the reduction is of similar magnitude in both the training and test sets 
(there is also some reduction of false positives in the training set, but this is a less prominent 
result).  The principal effect of the parameterization is to take into account the fact that there is 
some noise in the induced fit calculation energetics, reflected in the 5.26 kcal/mole energy 
window and scaling factor of 0.58. The noise is a combination of imperfect sampling and 
residual errors in the continuum solvent free energy model; the parameters suggest that there is a 
slight overestimation of the relative energetics of poses close in energy. Buffering and scaling 
the contribution from this term enables a (small) number of secondary sites to be recognized by 
the model as contributing to the reactivity, without increasing the number of false positives.  As 
noted above, the intrinsic reactivity appears to have less noise associated with it, which is not 













Table 3.3. Summary of results for the training set. 
Symbol Compound Name 
Physical IDSite Fitted IDSite 
TP FP FN TP FP FN 
1 4-methoxyamphetamine 1 0 0 1 0 0 
2 Amitriptyline 2 2 0 2 0 0 
3 Aprindine 4 0 1 5 0 0 
4 Brofaromine 1 0 0 1 0 0 
5 Bufuralol 0 1 1 1 0 0 
6 Carvedilol 1 0 2 2 0 1 
7 Cinnarizine 0 2 1 0 2 1 
8 Clomipramine 1 0 1 1 0 1 
9 Codeine 1 0 0 1 0 0 
10 Desipramine 2 0 0 2 0 0 
11 Dextromethorphan 1 0 0 1 0 0 
12 Dihydrocodeine 1 1 0 1 0 0 
13 Ethylmorphine 1 0 0 1 0 0 
14 Flunarizine 1 0 0 1 0 0 
15 Fluperlapine 1 0 0 1 0 0 
16 Hydrocodone 1 0 0 1 0 0 
17 Imipramine 2 0 0 2 0 0 
18 Indoramine 1 0 0 1 0 0 
19 MDMA 1 0 0 1 0 0 
20 Methamphetamine 1 0 0 1 2 0 
21 Methoxyphenamine 2 0 0 2 0 0 
22 Metoprolol 1 0 1 2 0 0 
23 Mexiletine 2 0 1 2 0 1 
24 Mianserin 1 0 0 1 0 0 
25 Mirtazapine 0 1 1 1 1 0 
26 Nortriptyline 1 1 0 1 0 0 
27 Ondansetron 2 0 0 1 0 1 
28 Paroxetine 1 0 0 1 0 0 
29 Perhexiline 2 0 0 2 0 0 
30 Propafenone 1 1 0 1 1 0 
31 Propranolol 2 2 0 2 1 0 
32 Tamoxifen 1 0 0 1 0 0 
33 Terfenadine 3 0 0 3 0 0 
34 Tiracizine 1 2 0 1 1 0 
35 Tropisetron 2 0 1 3 0 0 
36 Venlafaxine 1 0 0 1 0 0 





Table 3.4. Summary of results for the test set. 
Symbol Compound Name 
Physical IDSite Fitted IDSite 
TP FP FN TP FP FN 
37 Atomoxetine 0 1 1 1 2 0 
38 Bicifadine 1 2 0 1 0 0 
39 Bupranolol 1 0 0 1 0 0 
40 Carteolol 1 1 0 1 0 0 
41 Chlorpromazine 1 0 0 1 0 0 
42 EMAMC 1 0 0 1 0 0 
43 Encainide 1 1 0 1 1 0 
44 Harmaline 1 0 0 1 0 0 
45 Harmine 1 1 0 1 1 0 
46 Ibogaine 1 0 0 1 0 0 
47 MAMC 1 0 0 1 0 0 
48 MMAMC 1 0 0 1 0 0 
49 MOPPP 1 0 0 1 0 0 
50 Oxycodone 1 0 0 1 0 0 
51 Spirosulfonamide 2 0 0 2 0 0 
52 Timolol 2 0 2 4 0 0 
53 Tolterodine 0 1 1 1 1 0 
54 Tramadol 1 1 0 1 1 0 
55 Tyramine 2 0 0 2 0 0 
56 Zotepine 1 0 0 1 0 0 
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Figure 3.9 (continued). IDSite predicted results for the test set. 
 
A second question of interest is whether the various intensive sampling components of the 
algorithm actually improve the predictive capability.  In order to analyze the importance of each sampling 
stage in IDSite, ROC (Receiver Operating Characteristic) curves were calculated (Figure 3.10A) to 
compare three reduced methods using the fitted score to the full method using physical and fitted scores. 
As mentioned in the Methods section, each refinement stage performs a constrained minimization, 
followed by sampling with MCM simulations. After Glide docking, the prediction can be made after 
minimization in the first refinement stage (referred to as “docking+minimization”), after the sampling in 
the first refinement stage (referred to as “no Ref2”), or after the minimization in the second refinement 
stage (referred to as “no sampling in Ref2”). Higher energy cutoff (150 kcal/mol, instead of 24 kcal/mol) 
and distance cutoff (8.0 Å, instead of 2.6 Å for sp
3
 and 2.08 Å for sp
2
 hybridized atoms) are adjusted for 
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(4.75 and 1.46 kcal/mol are used for the results shown in Table 3.3 and 3.4 for the physical and fitted 
scores, respectively) is varied at 0.5 kcal/mol interval from 0.0 to 100 kcal/mol, which represent the true 
positive rate (y-axis) and the corresponding false positive rate (x-axis) of the methods. True positive rate 
and false positive rate are calculated according to Eq. 3.5, 
                   
                        
                                      
 
                    
                         
                                         
 
                           (Eq. 3.5) 




carbon atoms which undergo hydroxylation or O-
dealkylation) identified by experiments as well as predicted correctly by IDSite, and the false positives 
are non-SOMs (nonhydrogen atoms) but mispredicted by IDSite as hydroxylated/dealkylated by CYP2D6. 





 carbon atoms with bonded hydrogen atoms, those sites (carbon atoms or heteoatoms) 
which potentially undergo other metabolic reactions such as N-dealkylation and oxidation are currently 
considered as non-SOMs in our preliminary study.  
The ROC curves in Figure 3.10A indicates that at the same false positive rate (sensitivity), the 
false positive rate decreases with more sampling and the full IDSite method always has the lowest false 
positive rate (the highest specificity) with both scoring models. It is interesting that the physical score 
derived from the basic physical chemistry model is very close to the fitted score. For the reduced methods, 
there is an obvious trend that increasing the sampling efforts yields substantially higher specificity at each 
stage. This means that using the IDSite scoring models in conjunction with binding requirements, 








Figure 3.10. (A) ROC curves comparing the full IDSite method to the reduced methods. (B) 




   
In Figure 3.10B we compare the Physical IDSite and Fitted IDSite results to results from 
Sheridan et al.,
41
 who evaluated true positive and false positive rates, using the same ROC metric that we 
employ, for their test set of CYP2D6 ligands. The test set employed in ref. 
41
 is different in detail from the 






molecules given in ref.
41
. Hence, while the comparison is not completely rigorous, it is a reasonable way 
to estimate relative performance. It can be seen that given the caveat above, both Physical IDSite and 
Fitted IDSite substantially outperform both MetaSite and the in house Merck QSAR-based approached 
plotted in Figure 3.10B.  To recover 90% of true positives, the QSAR method included roughly 20% of 
false positives, whereas MetaSite included 40% of false positives. In contrast, IDSite incorporated only 
~1% of false positives. This is a qualitative transformation of performance that has significant 
implications for use in drug discovery applications, as does the availability of a predicted three 
dimensional structure that is likely to be quite accurate.   
 So far, only the apo enzyme structure of CYP2D6 has been determined by X-ray crystallography. 
In order to investigate the capability of IDSite in modeling the induced-fit effects and understand the 
effects of the hierarchical sampling, several compounds of various sizes and flexibility were selected to 
analyze the structural and energetic changes at each stage.  
 It is very common that the poses from docking that have the SOM close to the ferryl oxygen are 
not among the top poses considered by Glide SP scoring. For example, the pose with the shortest distance 
(1.8 Å) is ranked 6
th
 in the case of 4-methoxyaphetamine; the pose (1.4 Å) that leads to prediction of O-
demethylation is ranked 20
th
 for the case of metoprolol. Further, it is also possible for some cases (e.g. 
fluperlapine) that none of the poses have the SOM close enough to the ferryl oxygen. Therefore, it is very 
difficult to make specific predictions with only a small distance cutoff and a few top poses from docking. 
In order to improve the sensitivity as well as the specificity of the predictions, it appears to be necessary 
to employ the refinement stages.  
Focusing on the distance between the site(s) of metabolism observed experimentally, we 
investigated the Boltzmann averaged energy and distance from the site(s) to the ferryl oxygen over all the 
poses sampled at any even numbered step. Given the strong harmonic constraints applied in the 




first refinement is usually small ranging from 4 to 25 kcal/mol. However, the energy change during the 
second refinement stage is quite different for small ligands as compared to large ligands. For ligands as 
small as 4-methoxyaphetamine, the energy of the poses fluctuated within the range of 12 kcal/mol and the 
lowest energy structure was obtained at the early steps. In contrast, the energy can decrease by more than 
60 kcal/mol during the sampling of the second refinement stage for flexible or bulky ligands such as 
fluperlapine. For such cases it is often not until the end of the simulation that the low energy structure is 
sampled. This implies that the second refinement plays an important role in optimizing the structure for 
bulky or flexible compounds.  
Skipping the second refinement, about 40% of the compounds (24/56) in the training set have the 
same results as obtained from the full protocol and most of them are small compounds like 
4-methoxyaphetamine, MDMA, MAMC, etc. This observation is consistent with our discussion above 
that links the need for extended refinement to the presence of large, bulky ligands where protein induced-
fit effects are significant, and where optimization of the free energy of the reactive binding complex can 
pose great difficulties due to various types of energy barriers and additional degrees of freedom to explore 
in the ligand. 
 
 
Figure 3.11. The energy and distance (constrained atom to the ferryl oxygen) changes during the 






Figure 3.12. The energy and distance (constrained atom to the ferryl oxygen) changes during the 
MCM simulation during the first (A) and the second (B) refinements for dextromethorphan. 
  
 
Figure 3.13. The energy and distance (constrained atom to the ferryl oxygen) changes during the 
MCM simulation during the first (A) and the second (B) refinements for fluperlapine. 
 
Analysis of Induced-fit Effects 
P450 enzymes are believed to have high flexibility in adjusting their active site to 
accommodate a large variety of substrates. In order to model such induced fit effects, sufficient 
sampling provided by the two refinement stages of IDSite is critical as demonstrated in the 
previous section. In order to further investigate the capability of IDSite in modeling induced-fit 
effects, we calculated the average absolute change for each dihedral angle of the protein side 
chains in the binding box in comparison to the minimized crystal structure of CYP2D6. The 
largest change of all the chi angles for each residue is used to represent the change for that 
residue. Figure 3.14 illustrates the induced-fit effects by showing the largest change for each 




IDSite is able to model induced-fit effects required to correctly identify the “bio-active” 
conformation of the ligands by changing the side-chain orientations in the active site. Phe120 
and Phe483 with bulky side chains have changes as large as 40° and 60°, respectively. However, 
the magnitude of their induced fit effects depends strongly on the ligand size. Between these two 
Phe residues in the binding box, Met374 has the most significant change (108°) because a small 
rotation in the Phe side chains can cause a big adjustment in Met374. Compared to the large 




Figure 3.14. Illustration of the induced-fit effects modeled by IDSite. Cyan-white-red scheme is 
used to show the side chains from the least changed to the most changed, defined as the 
maximum mean absolute dihedral angle change for each residue. 
 
 
The above mentioned trends are illustrated in Figures 3.15-3.17, which compare the 
docked structures leading to the SOM of 4-methoxyamphetamine (PMA), fluperlapine, and 




model. Analogous figures can be found for all our predictions in the supplementary information. 
One striking example of induced-fit effects involves Phe120. For small ligands such as PMA the 
benzene ring conformation of Phe120 changes only slightly (Figure 3.15) while it has to move 
out of the way for larger ligands such as fluperlapine (Figure 3.16) or metoprolol (Figure 3.17), 
therefore rotating by almost 90°. Interestingly, for compounds with multiple sites of metabolism, 
such as metoprolol (Figure 3.17), different binding modes leading to different SOMs have very 
different conformations of the Phe120 side chain as well. The structures produced by IDSite 
clearly highlight the importance of induced fit effects for CYP2D6 metabolism and provide an 




Figure 3.15. (A) The lowest energy pose in the second refinement stage for 
4-methoxyaphetamine. Orange sphere = “dummy” ferryl oxygen, green sphere = experimental 
and predicted SOM. (B) Comparison of side chains important for induced-fit effects. Crystal 
structure (green, PDBID: 2F9Q) minimized with the VSGB 2.0 model and superimposed onto 
the lowest energy pose with 4 methoxyamphetamine (salmon). Large dihedral changes are seen 









Figure 3.16. (A) The lowest energy pose in the second refinement stage for fluperlapine. Orange 
sphere = “dummy” ferryl oxygen, green sphere = experimental and predicted SOM. (B) 
Comparison of side chains important for induced fit effects. Crystal structure (green, PDBID: 
2F9Q) minimized with the VSGB 2.0 model and superimposed onto the lowest energy pose with 
Fluperlapine (salmon). Large dihedral changes are seen for Phe120 (Δchi2, 73°), Glu216 (Δchi1, 






Figure 3.17. (A) The lowest energy poses in the second refinement stage for metoprolol benzylic 
hydroxylation. (B) Comparison of side chains important for induced fit effects for metoprolol 
benzylic hydroxylation. (C) The lowest energy poses in the second refinement stage for 
metoprolol O-dealkylation. (D) Comparison of side chains important for induced fit effects for 
metoprolol O-dealkylation. For (A) and (C) orange spheres = “dummy” ferryl oxygen, green 
spheres = experimental and predicted SOMs. For (B) and (D) crystal structure (green, PDBID: 
2F9Q) minimized with the VSGB 2.0 model and superimposed onto the lowest energy poses 
with metoprolol (salmon). For benzylic hydroxylation, large dihedral changes are seen for 
Glu216 (Δchi1, 60°), Asp301 (Δchi2, 66°), Met374 (Δchi3, 112°), and Phe483 (Δchi1, 40°); for 
O-dealkylation, large dihedral changes are seen for Phe120 (Δchi2, 67°), Glu216 (Δchi2, 50°), 






         
Importance of Structural Effects in Determining SOMs 
The two main competing factors in determining the SOMs with P450 enzymes are the 
intrinsic reactivities of the ligand sites and the geometric fit of the ligand in the active site. As 
mentioned in the Methods section, IDSite considers both of these effects in determining the 
SOMs, which enables it to select the correct SOM even for difficult cases, where the intrinsic 
reactivity favors a site that is not experimentally observed to be oxidized. For these cases, the 
structural fit of the ligand with the receptor (i.e., how easily the ligand site can reach the ferryl 
oxygen) mainly determines the SOM. Therefore, the structures and energies of the poses, with 
consideration of the receptor, have to be utilized. Three cases are used here to demonstrate the 
role of a receptor (CYP2D6) in determining the sites of metabolism.  
 
 
Figure 3.18. (A) The lowest energy pose in the second refinement stage for brofaromine. Orange 
sphere = “dummy” ferryl oxygen, green sphere = experimental and predicted SOM. (B) Intrinsic 
reactivities (red) for each site and the relative energy (blue) of the poses with the corresponding 







The first case is brofaromine, for which experiments show that the major metabolic 
pathway is O-demethylation mediated by CYP2D6.
138
 The intrinsic reactivity of the site of 
metabolism (4.7 kcal/mol) is very close to those of sites on the aromatic rings (non sites of 
metabolism, 3.3-4.9 kcal/mol) (Figure 3.18). Due to the receptor geometry, it is impossible for 
the atoms on the furan ring to approach the ferryl oxygen while still forming the required salt 
bridge with either Glu216 or Asp301. Therefore, no qualified poses were found leading to a 
reaction on the furan ring. Although we found qualified poses for all the sites on the benzene ring, 
those poses are all strongly disfavored energetically by more than 20 kcal/mol. This indicates 
that taking the interactions between the ligand and the receptor into account, IDSite is able to 




Figure 3.19. (A) The lowest energy pose in the second refinement stage for nortriptyline. Orange 
sphere = “dummy” ferryl oxygen, green sphere = experimental and predicted SOM. (B) Intrinsic 
reactivities (red) for each site and the relative energy (blue) of the poses with the corresponding 







A second interesting case is nortriptyline, since the two sites on the 7-membered aliphatic 
ring are difficult to distinguish only with their intrinsic reactivity as they are almost equally 
reactive. However, experiments show that only the (E)-10 site of nortriptyline is metabolized.
139
 
The poses generated by IDSite with the (Z)-10 site close to the ferryl oxygen are all at least 10 
kcal/mol higher in energy compared to the poses with the (E)-10 atom close to the ferryl oxygen. 
Such an energy gap is large enough for IDSite to correctly determine the (E)-isomer as the only 
metabolite. While structural effects are therefore clearly very important to determine 
nortriptylene’s SOM, the intrinsic reactivities also play a key role. This is again nicely illustrated 
with the example of nortriptyline, where a simply structure based method (without considering 
intrinsic reactivities) would predict the SOM as being an aromatic hydroxylation due to the 
favorable energy of the corresponding poses. Therefore, IDSite is able to correctly balance the 
subtle effects stemming from intrinsic reactivity and structural fit. 
 
Methoxyphenamine is another case where the joint effects of intrinsic reactivity and the 
structural fit lead to the correct predictions. Methoxyphetamine is metabolized through O-
demethylation and aromatic hydroxylation mediated by CYP2D6.140 These two sites not only 
have very close intrinsic reactivities (5.7 and 6.3 kcal/mol, Figure 3.20), but their lowest energy 
poses also have very similar energies. The non-SOMs are not selected by IDSite because of 






Figure 3.20. The lowest energy pose in the second refinement stage for methoxyphenamine. 
Orange sphere = “dummy” ferryl oxygen, green sphere = experimental and predicted SOM. (A) 
Aromatic hydroxylation. (B) O-demethylation. (C) Intrinsic reactivities (red) for each site and 
the relative energy (blue) of the poses with the corresponding site constrained to the ferryl 
oxygen. The SOM observed experimentally is marked with a green circle. 
     
Computational Cost 
On a single 2.2 GHz AMD Opteron Processor 6174, the average CPU time required for a 
typical IDSite calculation (e.g. with a compound with 3 rotatable bonds) is about 448 hours, of 
which about 11% of the time is spent on the first refinement stage and 89% on the second 
refinement. On 20 such processors the calculation takes 22 hours. The initial Glide docking step 
on a single processor takes about 10 min. The computational cost of PLOP refinement is 








             A novel approach for the prediction of experimentally observable cytochrome P450 sites 
of metabolism, IDSite, has been developed and applied it to a data set for the 2D6 P450 isoform. 
It has shown remarkably high sensitivity and specificity using a structure-based model, 
representing a major advance as compared to alternatives in the literature, including various 
types of ligand-based models. The method delivers not only accurate SOM predictions, but also 
three dimensional structures of the protein-ligand complex, including induced fit effects (which 
are quite significant), for every SOM identified by the algorithm. 
CYP2D6 was selected as the initial target because the binding of a positive nitrogen in 
the ligand to an acidic group in the protein created an additional constraint that was useful in 
limiting sampling and achieving reliable poses in the induced fit docking effort.  Other important 
P450 isoforms, such as 2C9 and 3A4,  may be more difficult to model in this fashion as they lack 
such a salt bridge constraint; nevertheless, even if additional sampling effort is required, it should 
be possible to obtain successful results given the performance of the conformational energy and 
reactivity models that have seen in the present work. The development of models for additional 
isoforms, and to additional ligand test sets, is ongoing in our laboratory. Ultimately, predictive 






3.5. Appendix for Chapter 3 
1. Data Set 
The details of our data set of CYP2D6 substrates are listed in Table 3.5. Compounds 1-36 
were selected from the work of de Groot et al.
137
 4 compounds from the data set of de Groot 
(debrisoquine, GBR-12909, guanoxan, and phenformin) were not included, because the 
metabolic pathways and the role of CYP2D6 in these pathways were not clear to us.
37,141-143
 
Compound 37-56 were collected from the review of Wang et al.,
37
 and further examined by 
carefully inspecting the original experimental literature. (Table 3.5) 
 
Table 3.5. Details of the data set. 








O-dealkylation 1 11 
144
 
2 amitriptyline benzylic hydroxylation 2 19 
145
 
3 aprindine aromatic hydroxylation 5 19 
146
 
37 atomoxetine aromatic hydroxylation 1 18 
147
 
38 (±)-bicifadine benzylic hydroxylation 1 12 
148
 
4 brofaromine O-dealkylation 1 17 
138
 
5 (±)-bufuralol benzylic hydroxylation 1 18 
149,150
 
39 (±)-bupranolol benzylic hydroxylation 1 17 
151
 
40 (±)-carteolol aromatic hydroxylation 1 20 
152
 





41 chlorpromazine aromatic hydroxylation 1 20 
154
 
7 cinnarizine aromatic hydroxylation 1 27 
155
 
8 clomipramine aromatic hydroxylation 2 20 
156
 
9 codeine O-dealkylation 1 21 
157
 
10 desipramine aromatic hydroxylation 2 18 
158
 
11 dextromethorphan O-dealkylation 1 19 
159
 
12 dihydrocodeine O-dealkylation 1 21 
160
 
42 EMAMC O-dealkylation 1 16 
161
 
43 (±)-encainide O-dealkylation 1 25 
162
 






14 flunarizine aromatic hydroxylation 1 29 
155
 
15 fluperlapine 7-hydroxylation 1 22 
164
 
44 harmaline O-dealkylation 1 15 
165
 
45 harmine O-dealkylation 1 15 
165
 
16 hydrocodone O-dealkylation 1 21 
166,167
 
46 ibogaine O-dealkylation 1 22 
168
 
17 imipramine aromatic hydroxylation 2 19 
158
 
18 indoramine 6-hydroxylation 1 25 
169
 
47 MAMC O-dealkylation 1 14 
161
 
19 (±)-MDMA O-dealkylation 1 13 
170
 
20 (±)-methamphetamine 4-hydroxylation 1 10 
171
 















24 (±)-mianserin aromatic hydroxylation 1 19 
174
 
25 (±)-mirtazapine aromatic hydroxylation 1 19 
175
 
48 MMAMC O-dealkylation 1 15 
161
 
49 (±)-MOPPP O-dealkylation 1 16 
176
 
26 nortriptyline benzylic hydroxylation 1 19 
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50 oxycodone O-dealkylation 1 22 
178
 
28 paroxetine O-dealkylation 1 23 
179
 
29 (±)-perhexiline aliphatic hydroxylation 2 18 
180
 
30 (±)-propafenone aromatic hydroxylation 1 24 
181
 
31 (±)-propranolol aromatic hydroxylation 2 17 
182
 
51 spirosulfonamide aliphatic hydroxylation 2 25 
128
 
32 tamoxifen aromatic hydroxylation 1 27 
183
 
33 (±)-terfenadine t-Butyl hydroxylation 3 32 
184
 
52 (s)-timolol aliphatic hydroxylation 4 17 
185
 
34 tiracizine O-dealkylation 1 26 
186
 





54 (±)-tramadol O-dealkylation 1 18 
188
 









55 tyramine aromatic hydroxylation 2 8 
189
 
36 (±)-venlafaxine O-dealkylation 1 19 
190,191
 
56 zotepine aromatic hydroxylation 1 20 
192
 
 TOTAL  82 1075  
 
2. Data used to plot Figure 3.7 
We show below the model compounds and the data which were used to plot Figure 3.7. 
Only a doublet spin state was considered for the spin state of Compound I and the transition 
states. 
 
Table 3.6. Comparison of activation energies calculated with the heme model and with the 
methoxy radical model. 
Model compound Hydroxylated position 
Heme model  
(kcal/mol) 
Methoxy radical model  
(kcal/mol) 
benzene  20.51 8.66 
toluene Ortho- 17.15 6.22 
 Meta- 18.86 8.27 
 Para- 18.00 7.58 
 Alpha- 15.72 5.16 
anisole Ortho- 16.29 5.31 
 Meta- 18.76 8.55 
 Para- 16.01 4.71 
 Beta- 16.18 6.63 
ethane  21.58 10.37 
propane 2- 18.31 7.80 
ethanol 1- 12.73 2.36 
 2- 17.35 6.90 
t-Butylebenzene Beta- 20.82 9.33 
dimethylether  15.03 3.90 
dimethylanisole Meta- 16.54 6.07 




3. Docked Structures used for the correct prediction of SOMs. Only the lowest energy poses 


































































































































































4. Full lists of dihedral angle changes for the cases we listed in the main text 
Table 3.7. Dihedral angles of the lowest energy pose (with the SOM atom constrained) for 
4-methoxyaphetamine. 
4-methoxyamphetamine Crystal Structure Refine 1 Refine 2 
    Start End Start End 
119 VAL chi1 -162.5 -162.5 -162.5 -81.8 -81.9 
120 PHE chi1 -162.6 -135.9 -138.2 -166.5 -167.1 
  chi2 86.1 128.8 136.7 85.2 83.3 
121 LEU chi1 -60.2 -58.9 -58.6 -56.8 -55.7 
  chi2 -179.9 -177.3 -178.6 175.9 177.6 
213 LEU chi1 -179.2 178.4 179.7 -173.1 -178.5 
  chi2 60.1 56.5 56.4 55.3 53.1 
214 LYS chi1 -162.8 -179.8 -154.2 178.3 173.9 
  chi2 -171.3 168.7 -171.0 -176.4 -178.0 
  chi3 -168.1 160.9 90.1 144.8 154.8 
  chi4 -65.7 -71.5 -168.5 -164.1 -165.8 
215 GLU chi1 -77.1 -74.6 -72.8 -78.6 -82.4 
  chi2 168.7 170.4 169.7 174.6 176.5 
  chi3 -16.4 -18.4 -19.8 -22.5 -15.3 
216 GLU chi1 -10.8 -68.1 -66.6 171.8 -71.8 
  chi2 -171.8 -176.4 -178.9 169.2 179.9 
  chi3 97.5 108.9 -68.9 -109.1 125.4 
217 SER chi1 75.9 75.9 75.9 68.1 73.4 
219 PHE chi1 -72.5 -72.5 -72.5 -76.3 -73.8 




220 LEU chi1 -76.7 -76.7 -76.7 -59.1 -60.5 
  chi2 164.6 164.6 164.6 -176.3 -179.6 
221 ARG chi1 63.7 63.7 63.7 -67.1 -69.5 
  chi2 -169.0 -169.0 -169.0 164.2 178.9 
  chi3 178.5 178.5 178.5 -148.8 -73.7 
  chi4 -148.4 -148.4 -148.4 -161.1 172.1 
  chi5 1.0 1.0 1.0 4.8 6.3 
222 GLU chi1 -124.0 -124.0 -124.0 -58.4 -69.2 
  chi2 75.3 75.3 75.3 -58.7 -65.1 
  chi3 45.3 45.3 45.3 139.9 -24.9 
301 ASP chi1 -71.6 -83.2 -79.7 -74.7 -73.9 
  chi2 -170.6 179.5 -164.9 131.0 134.1 
302 LEU chi1 -70.5 -70.5 -70.5 -73.4 -72.9 
  chi2 166.1 166.1 166.1 164.0 164.0 
303 PHE chi1 -99.0 -99.0 -99.0 -165.6 -165.0 
  chi2 -70.6 -70.6 -70.6 99.5 98.2 
304 SER chi1 68.5 56.7 58.5 57.7 55.3 
307 MET chi1 179.2 179.2 179.2 177.0 176.7 
  chi2 -165.7 -165.7 -165.7 -93.2 -93.6 
  chi3 -37.7 -37.7 -37.7 -73.2 -73.9 
308 VAL chi1 63.2 63.2 63.2 63.5 69.2 
309 THR chi1 58.4 54.7 54.8 54.7 52.9 
310 THR chi1 -54.8 -54.8 -54.8 -30.7 -31.1 
311 SER chi1 177.2 177.2 177.2 -179.3 -177.5 
312 THR chi1 -65.2 -65.2 -65.2 -64.7 -67.5 
313 THR chi1 -62.4 -62.4 -62.4 -54.1 -52.3 
368 ASP chi1 -176.0 -176.0 -176.0 -61.6 -62.4 
  chi2 18.7 18.7 18.7 -101.1 -100.6 
369 ILE chi1 62.1 62.1 62.1 -62.2 -50.1 
  chi2 140.9 140.9 140.9 112.7 144.5 
370 VAL chi1 -134.7 -134.7 -134.7 -168.9 -164.6 
371 PRO chi1 -25.7 -25.7 -25.7 26.9 26.5 
  chi2 30.6 30.6 30.6 -29.1 -28.7 
372 LEU chi1 -57.3 -57.3 -57.3 -57.0 -57.6 
  chi2 -179.2 -179.2 -179.2 174.8 175.3 
374 MET chi1 179.8 179.8 179.8 176.5 177.2 
  chi2 45.7 45.7 45.7 56.6 58.0 
  chi3 48.9 48.9 48.9 165.3 162.7 
375 THR chi1 -174.7 -174.7 -174.7 51.8 51.9 




481 PHE chi1 172.6 172.6 172.6 -85.7 -88.9 
  chi2 72.7 72.7 72.7 66.2 69.8 
483 PHE chi1 -132.4 -133.2 -131.5 179.6 -179.9 
  chi2 83.4 89.6 89.3 58.7 64.8 
484 LEU chi1 -156.8 -156.8 -156.8 -74.1 -83.7 
  chi2 158.8 158.8 158.8 96.4 91.4 
485 VAL chi1 -30.4 -30.4 -30.4 -172.1 -172.1 
486 SER chi1 -77.2 -77.2 -77.2 -179.4 179.7 
 
 
Table 3.8. Dihedral angles of the lowest energy pose (with the SOM atom constrained) for 
fluperlapine. 
fluperlapine Crystal Structure Refine 1 Refine 2 
    Start End Start End 
120 PHE chi1 -162.6 -140.7 -137.5 -167.5 -125.0 
  chi2 86.1 142.6 137.2 117.7 159.5 
215 GLU chi1 -77.1 -77.1 -76.3 -83.4 -81.4 
  chi2 168.7 172.2 172.5 175.1 179.0 
  chi3 -16.4 -15.6 -17.0 -17.4 -21.3 
216 GLU chi1 -10.8 -73.3 -69.3 -71.3 -75.2 
  chi2 -171.8 -166.0 -178.1 -173.0 -175.2 
  chi3 97.5 -113.2 -82.5 145.7 -48.8 
217 SER chi1 75.9 75.9 75.9 75.2 -57.9 
219 PHE chi1 -72.5 -72.5 -72.5 -73.6 -62.2 
  chi2 106.0 106.0 106.0 118.9 114.8 
220 LEU chi1 -76.7 -76.7 -76.7 -74.1 -54.8 
  chi2 164.6 164.6 164.6 153.4 172.2 
221 ARG chi1 63.7 63.7 63.7 67.4 -147.4 
  chi2 -169.0 -169.0 -169.0 -172.5 173.6 
  chi3 178.5 178.5 178.5 -172.7 63.2 
  chi4 -148.4 -148.4 -148.4 -135.5 -106.9 
  chi5 1.0 1.0 1.0 0.5 -2.0 
222 GLU chi1 -124.0 -124.0 -124.0 177.1 -49.2 
  chi2 75.3 75.3 75.3 64.8 -57.9 
  chi3 45.3 45.3 45.3 8.4 144.5 
301 ASP chi1 -71.6 -79.7 -80.8 -93.0 -84.4 
  chi2 -170.6 -154.7 -164.7 -34.6 -54.8 
302 LEU chi1 -70.5 -70.5 -70.5 -70.5 -71.7 
  chi2 166.1 166.1 166.1 167.2 166.0 




  chi2 -70.6 -70.6 -70.6 -71.3 -83.8 
304 SER chi1 68.5 61.4 62.4 62.0 67.1 
307 MET chi1 179.2 179.2 179.2 177.7 -175.3 
  chi2 -165.7 -165.7 -165.7 -176.8 -133.9 
  chi3 -37.7 -37.7 -37.7 -48.4 67.8 
308 VAL chi1 63.2 63.2 63.2 48.9 -175.3 
309 THR chi1 58.4 50.2 50.4 44.4 46.7 
310 THR chi1 -54.8 -54.8 -54.8 -53.2 -13.9 
311 SER chi1 177.2 177.2 177.2 -179.1 51.1 
312 THR chi1 -65.2 -65.2 -65.2 -63.0 -62.6 
313 THR chi1 -62.4 -62.4 -62.4 -55.3 -56.0 
368 ASP chi1 -176.0 -176.0 -176.0 -159.0 -153.6 
  chi2 18.7 18.7 18.7 -2.5 -7.4 
369 ILE chi1 62.1 62.1 62.1 78.4 -55.3 
  chi2 140.9 140.9 140.9 106.4 97.0 
370 VAL chi1 -134.7 -134.7 -134.7 -156.1 -167.2 
371 PRO chi1 -25.7 -25.7 -25.7 -23.9 29.3 
  chi2 30.6 30.6 30.6 27.4 -33.1 
372 LEU chi1 -57.3 -57.3 -57.3 -57.7 -60.5 
  chi2 -179.2 -179.2 -179.2 177.3 174.9 
374 MET chi1 179.8 179.8 179.8 175.9 176.0 
  chi2 45.7 45.7 45.7 45.0 73.0 
  chi3 48.9 48.9 48.9 46.0 -84.3 
375 THR chi1 -174.7 -174.7 -174.7 -178.1 71.5 
480 VAL chi1 -147.9 -147.9 -147.9 -175.3 -176.0 
481 PHE chi1 172.6 172.6 172.6 178.9 176.9 
  chi2 72.7 72.7 72.7 65.7 72.2 
483 PHE chi1 -132.4 -134.7 -134.5 -126.8 -147.0 
  chi2 83.4 89.5 89.4 115.7 -10.4 
484 LEU chi1 -156.8 -156.8 -156.8 -155.1 -144.8 
  chi2 158.8 158.8 158.8 164.7 141.2 
485 VAL chi1 -30.4 -30.4 -30.4 -58.5 169.3 
486 SER chi1 -77.2 -77.2 -77.2 -63.5 62.4 
 
 
Table 3.9. Dihedral angles of the lowest energy pose (with the SOM atom constrained) for 
metoprolol (benzylic hydroxylation). 
metoprolol Benzylic Hydroxylation Crystal Structure Refine 1 Refine 2 
    Start End Start End 




120 PHE chi1 -162.6 -171.2 -167.7 -178.5 -166.1 
  chi2 86.1 50.0 82.0 107.4 68.6 
121 LEU chi1 -60.2 -58.3 -62.2 -69.6 -55.4 
  chi2 -179.9 178.1 179.6 -172.4 178.5 
213 LEU chi1 -179.2 178.2 178.5 -172.1 179.6 
  chi2 60.1 63.2 54.0 62.8 53.4 
214 LYS chi1 -162.8 177.9 176.7 177.6 173.8 
  chi2 -171.3 170.6 -178.7 172.3 -176.2 
  chi3 -168.1 162.8 149.7 163.4 156.7 
  chi4 -65.7 -71.5 -164.8 -71.0 -167.0 
215 GLU chi1 -77.1 -76.2 -76.5 -81.8 -83.4 
  chi2 168.7 169.7 171.7 174.6 175.2 
  chi3 -16.4 -19.1 -19.4 -24.2 -16.0 
216 GLU chi1 -10.8 -66.7 -69.3 -68.9 -71.0 
  chi2 -171.8 -170.4 -169.0 177.6 -174.4 
  chi3 97.5 179.4 -14.8 120.5 -44.9 
217 SER chi1 75.9 75.9 75.9 77.7 70.0 
219 PHE chi1 -72.5 -72.5 -72.5 -68.5 -74.1 
  chi2 106.0 106.0 106.0 120.4 -62.3 
220 LEU chi1 -76.7 -76.7 -76.7 -61.0 -57.1 
  chi2 164.6 164.6 164.6 173.0 -175.7 
221 ARG chi1 63.7 63.7 63.7 67.0 -70.1 
  chi2 -169.0 -169.0 -169.0 -172.7 174.7 
  chi3 178.5 178.5 178.5 -174.0 -70.5 
  chi4 -148.4 -148.4 -148.4 -138.5 -156.0 
  chi5 1.0 1.0 1.0 0.3 3.1 
222 GLU chi1 -124.0 -124.0 -124.0 172.9 -68.7 
  chi2 75.3 75.3 75.3 64.1 -64.9 
  chi3 45.3 45.3 45.3 12.1 153.1 
301 ASP chi1 -71.6 -68.9 -91.9 -72.0 -71.0 
  chi2 -170.6 -138.3 -56.2 -160.5 -56.3 
302 LEU chi1 -70.5 -70.5 -70.5 -66.8 -63.6 
  chi2 166.1 166.1 166.1 168.0 168.7 
303 PHE chi1 -99.0 -99.0 -99.0 -91.9 -89.3 
  chi2 -70.6 -70.6 -70.6 -69.7 111.8 
304 SER chi1 68.5 44.2 52.4 72.3 -174.5 
307 MET chi1 179.2 179.2 179.2 178.1 -166.4 
  chi2 -165.7 -165.7 -165.7 -177.6 -174.2 
  chi3 -37.7 -37.7 -37.7 -47.8 -45.0 




309 THR chi1 58.4 51.9 54.1 53.9 53.0 
310 THR chi1 -54.8 -54.8 -54.8 -46.8 -49.0 
311 SER chi1 177.2 177.2 177.2 180.0 52.1 
312 THR chi1 -65.2 -65.2 -65.2 -61.3 -66.4 
313 THR chi1 -62.4 -62.4 -62.4 -54.9 -54.0 
368 ASP chi1 -176.0 -176.0 -176.0 -161.2 -61.2 
  chi2 18.7 18.7 18.7 0.6 81.0 
369 ILE chi1 62.1 62.1 62.1 80.5 -62.4 
  chi2 140.9 140.9 140.9 113.7 111.1 
370 VAL chi1 -134.7 -134.7 -134.7 -77.8 -164.8 
371 PRO chi1 -25.7 -25.7 -25.7 -23.7 27.9 
  chi2 30.6 30.6 30.6 27.4 -30.2 
372 LEU chi1 -57.3 -57.3 -57.3 -57.1 -56.2 
  chi2 -179.2 -179.2 -179.2 178.2 176.1 
374 MET chi1 179.8 179.8 179.8 177.4 178.7 
  chi2 45.7 45.7 45.7 42.8 57.5 
  chi3 48.9 48.9 48.9 54.8 161.3 
375 THR chi1 -174.7 -174.7 -174.7 -178.5 52.1 
480 VAL chi1 -147.9 -147.9 -147.9 -175.0 -66.5 
481 PHE chi1 172.6 172.6 172.6 178.6 176.7 
  chi2 72.7 72.7 72.7 64.9 71.5 
483 PHE chi1 -132.4 -130.2 89.3 -115.8 173.0 
  chi2 83.4 89.7 -66.6 111.8 62.9 
484 LEU chi1 -156.8 -156.8 -156.8 -159.7 -84.6 
  chi2 158.8 158.8 158.8 161.9 91.4 
485 VAL chi1 -30.4 -30.4 -30.4 -57.9 167.9 
486 SER chi1 -77.2 -77.2 -77.2 -61.9 55.8 
 
 
Table 3.10. Dihedral angles of the lowest energy pose (with the SOM atom constrained) for 
metoprolol (O-demethylation). 
metoprolol O-demethylation Crystal Structure Refine 1 Refine 2 
    Start End Start End 
119 VAL chi1 -162.5 -162.5 -162.5 -162.9 -88.7 
120 PHE chi1 -162.6 -164.4 -155.1 -156.4 -162.1 
  chi2 86.1 95.0 107.2 -173.7 -160.5 
121 LEU chi1 -60.2 -54.2 -51.8 -75.9 -59.0 
  chi2 -179.9 177.8 174.6 -175.6 107.8 
213 LEU chi1 -179.2 175.0 177.2 -179.3 174.9 




214 LYS chi1 -162.8 179.6 -154.3 -179.2 -161.4 
  chi2 -171.3 169.5 -171.3 170.3 -169.8 
  chi3 -168.1 160.9 89.6 159.9 -66.8 
  chi4 -65.7 -71.6 -167.6 -71.0 174.6 
215 GLU chi1 -77.1 -74.9 -72.0 -76.3 -76.5 
  chi2 168.7 170.0 170.3 173.8 174.8 
  chi3 -16.4 -18.9 -20.1 -28.2 -27.0 
216 GLU chi1 -10.8 -67.6 -61.3 -72.0 -73.3 
  chi2 -171.8 -170.0 -161.3 -179.5 -175.0 
  chi3 97.5 59.7 62.0 125.2 148.2 
217 SER chi1 75.9 75.9 75.9 78.0 77.7 
219 PHE chi1 -72.5 -72.5 -72.5 -67.2 -67.4 
  chi2 106.0 106.0 106.0 120.1 128.3 
220 LEU chi1 -76.7 -76.7 -76.7 -59.6 -64.9 
  chi2 164.6 164.6 164.6 174.6 171.2 
221 ARG chi1 63.7 63.7 63.7 67.0 -66.0 
  chi2 -169.0 -169.0 -169.0 -172.8 -178.6 
  chi3 178.5 178.5 178.5 -174.4 -74.4 
  chi4 -148.4 -148.4 -148.4 -140.1 169.6 
  chi5 1.0 1.0 1.0 0.2 8.4 
222 GLU chi1 -124.0 -124.0 -124.0 172.8 175.3 
  chi2 75.3 75.3 75.3 63.9 65.1 
  chi3 45.3 45.3 45.3 12.6 8.2 
301 ASP chi1 -71.6 -68.4 -71.2 -77.2 -74.5 
  chi2 -170.6 -158.7 -162.1 162.9 -171.7 
302 LEU chi1 -70.5 -70.5 -70.5 -70.9 -68.9 
  chi2 166.1 166.1 166.1 167.0 163.6 
303 PHE chi1 -99.0 -99.0 -99.0 -91.0 -159.3 
  chi2 -70.6 -70.6 -70.6 -69.1 -82.5 
304 SER chi1 68.5 63.0 54.4 58.7 59.1 
307 MET chi1 179.2 179.2 179.2 173.9 176.3 
  chi2 -165.7 -165.7 -165.7 -176.7 -94.0 
  chi3 -37.7 -37.7 -37.7 -51.8 -73.7 
308 VAL chi1 63.2 63.2 63.2 53.3 62.8 
309 THR chi1 58.4 44.7 53.0 48.7 51.9 
310 THR chi1 -54.8 -54.8 -54.8 -48.4 -29.6 
311 SER chi1 177.2 177.2 177.2 178.6 -179.9 
312 THR chi1 -65.2 -65.2 -65.2 -62.5 -62.4 
313 THR chi1 -62.4 -62.4 -62.4 -55.4 -53.9 




  chi2 18.7 18.7 18.7 -0.2 172.0 
369 ILE chi1 62.1 62.1 62.1 79.5 81.7 
  chi2 140.9 140.9 140.9 107.1 105.6 
370 VAL chi1 -134.7 -134.7 -134.7 -166.6 -165.9 
371 PRO chi1 -25.7 -25.7 -25.7 -22.6 30.0 
  chi2 30.6 30.6 30.6 26.4 -34.1 
372 LEU chi1 -57.3 -57.3 -57.3 -58.8 -58.3 
  chi2 -179.2 -179.2 -179.2 178.7 179.0 
374 MET chi1 179.8 179.8 179.8 170.5 175.9 
  chi2 45.7 45.7 45.7 47.9 51.0 
  chi3 48.9 48.9 48.9 66.9 64.7 
375 THR chi1 -174.7 -174.7 -174.7 -179.0 50.4 
480 VAL chi1 -147.9 -147.9 -147.9 -174.9 -176.1 
481 PHE chi1 172.6 172.6 172.6 178.6 175.7 
  chi2 72.7 72.7 72.7 64.7 78.2 
483 PHE chi1 -132.4 -134.5 78.6 -115.7 61.8 
  chi2 83.4 90.4 148.4 109.7 88.1 
484 LEU chi1 -156.8 -156.8 -156.8 -158.9 156.2 
  chi2 158.8 158.8 158.8 172.2 145.2 
485 VAL chi1 -30.4 -30.4 -30.4 -57.5 168.6 






Chapter 4. Concluding Remarks 
This dissertation has described the development of computational approaches for 
practical structure-based drug discovery. The new accurate energy model (VSGB 2.0) has been 
presented along with advanced sampling algorithms for protein structure refinement. Given 
sufficient sampling, our methodology is able to select the structures with low RMSDs from the 
native ones. The VSGB 2.0 model has been applied to an accurate approach (IDSite) to predict 
P450-mediated metabolism. While competing computational methodologies for predicting 
SOMs are generally plagued by high false positive rates, IDSite correctly identifies almost all 
experimentally observed SOMs with only very few false positive predictions. Delivering such 
high accuracy, IDSite is likely to become practically useful in accelerating the drug discovery 
process. The example of IDSite shows that a highly accurate energy model in combination with 
efficient conformational sampling can indeed lead to transferrable, physical models for drug 
development. In addition to protein structure refinement and SOM prediction, the methodologies 
described in this dissertation can also contribute to building tools to study the mechanism of 
action (e.g. with QM/MM methods), to estimate binding affinities, and to assist fragment-based 
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